CA2562982A1 - Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications - Google Patents
Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications Download PDFInfo
- Publication number
- CA2562982A1 CA2562982A1 CA002562982A CA2562982A CA2562982A1 CA 2562982 A1 CA2562982 A1 CA 2562982A1 CA 002562982 A CA002562982 A CA 002562982A CA 2562982 A CA2562982 A CA 2562982A CA 2562982 A1 CA2562982 A1 CA 2562982A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- group
- aryl
- independently selected
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/055—Phenols the aromatic ring being substituted by halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted b-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.
Claims (76)
1. A composition comprising:
(a) a compound represented by Formula (II) below:
or a pharmaceutically acceptable salt or solvate thereof, (b) lactose monohydrate;
(c) microcrystalline cellulose;
(d) povidone;
(e) croscarmellose sodium;
(f) sodium lauryl sulfate; and (g) magnesium stearate.
(a) a compound represented by Formula (II) below:
or a pharmaceutically acceptable salt or solvate thereof, (b) lactose monohydrate;
(c) microcrystalline cellulose;
(d) povidone;
(e) croscarmellose sodium;
(f) sodium lauryl sulfate; and (g) magnesium stearate.
2. The composition according to claim 1, wherein (a) is said compound represented by Formula (II) is:
(II).
(II).
3. The composition according to claim 1 or 2, wherein the composition compnses:
Ingredient Weight percent of ingredient Compound of Formula (II),or a 10 pharmaceutically acceptable salt or solvate thereof Lactose monohydrate 55 Microcrystalline cellulose 20 Povidone 4 Croscarmellose sodium 8 Sodium lauryl sulfate 2 Magnesium stearate 1 Total 100.
Ingredient Weight percent of ingredient Compound of Formula (II),or a 10 pharmaceutically acceptable salt or solvate thereof Lactose monohydrate 55 Microcrystalline cellulose 20 Povidone 4 Croscarmellose sodium 8 Sodium lauryl sulfate 2 Magnesium stearate 1 Total 100.
4. The composition according to claim 1 or 2, wherein the composition compasses:
Ingredient milligrams of ingredient Compound of Formula (II) or a 10 pharmaceutically acceptable salt or solvate thereof, Lactose monohydrate 55 Microcrystalline cellulose 20 Povidone 4 Croscarmellose sodium 8 Sodium lauryl sulfate 2 Magnesium stearate 1 Total 100.
Ingredient milligrams of ingredient Compound of Formula (II) or a 10 pharmaceutically acceptable salt or solvate thereof, Lactose monohydrate 55 Microcrystalline cellulose 20 Povidone 4 Croscarmellose sodium 8 Sodium lauryl sulfate 2 Magnesium stearate 1 Total 100.
5. A composition comprising:
(a) a compound represented by Formula (II) below:
or a pharmaceutically acceptable salt or solvate thereof, (b)lactose;
(c)cellulose; and (d)povidone.
(a) a compound represented by Formula (II) below:
or a pharmaceutically acceptable salt or solvate thereof, (b)lactose;
(c)cellulose; and (d)povidone.
6. The composition according to claim 5, wherein the composition further comprises croscarmellose sodium.
7. The composition according to any one of claims 1 to 6, wherein the composition comprises about 0.1 to about 1000 milligrams of the compound of Formula (II) or a pharmaceutically acceptable salt or solvate thereof.
8. The composition according to claim 7, wherein the composition or therapeutic combination comprises about 0.25 to about 50 milligrams of the compound of Formula (II) or a pharmaceutically acceptable salt or solvate thereof.
9. The composition according to claim 8, wherein the composition comprises about 10 milligrams of the compound of Formula (II) or a pharmaceutically acceptable salt or solvate thereof.
10. The composition according to any one of claims 1 to 9, wherein the composition comprises about 0.1 to about 90 weight percent of lactose monohydrate based upon total weight of the composition.
11. The composition according to claim 10, wherein the composition comprises about 55 milligrams of lactose monohydrate.
12. The composition according to any one of claims 1 to 11, wherein the composition comprises about 0.1 to about 90 weight percent of microcrystalline cellulose based upon total weight of the composition.
13. The composition according to claim 12, wherein the composition comprises about 20 milligrams of microcrystalline cellulose.
14. The composition according to any one of claims 1 to 13, wherein the composition comprises about 0.1 to about 90 weight percent of povidone based upon total weight of the composition.
15. The composition or therapeutic combination according to claim 14, wherein the composition or therapeutic combination comprises about 4 milligrams of povidone.
16. The composition according to any one of claims 1 to 15, wherein the composition comprises about 0.1 to about 90 weight percent of croscarmellose sodium based upon total weight of the composition.
17. The composition according to claim 16, wherein the composition or therapeutic combination comprises about 8 milligrams of croscarmellose sodium.
18. The composition according to any one of claims 1 to 17, wherein the composition comprises about 0.1 to about 90 weight percent of sodium lauryl sulfate based upon total weight of the composition.
19. The composition according to claim 18, wherein the composition comprises about 2 milligrams of sodium lauryl sulfate.
20. The composition according to any one of claims 1 to 19, wherein the composition comprises about 0.1 to about 90 weight percent of magnesium stearate based upon total weight of the composition.
21. The composition according to claim 20, wherein the composition comprises about 1 milligram of magnesium stearate.
22. The composition according to any one of claims 1 to 21, wherein the composition further comprises at least one peroxisome proliferator-activated receptor activator.
23. The composition according to claim 22, wherein the at least one peroxisome proliferator-activated receptor activator is a fabric acid derivative selected from the group consisting of fenofibrate, clofibrate, gemfibrozil, ciprofibrate, bezafibrate, clinofibrate, binifibrate, lifibrol and mixtures thereof.
24. The composition according to claim 23, wherein the fabric acid derivative is fenofibrate.
25. The composition according to claim 23, wherein the fabric acid derivative is gemfibrozil.
26. The composition according to any one of claims 1 to 25, wherein the composition further comprises at least one cholesterol biosynthesis inhibitor.
27. The composition according to claim 26, wherein the at least one cholesterol biosynthesis inhibitor comprises at least one HMG CoA reductase inhibitor.
28. The composition according to claim 27, wherein the at least one HMG CoA reductase inhibitor is selected from the group consisting of lovastatin, pravastatin, fluvastatin, simvastatin, atorvastatin, rosuvastatin, cerivastatin and mixtures thereof.
29. The composition according to claim 28, wherein the at least one HMG CoA reductase inhibitor is simvastatin.
30. The composition according to claim 28, wherein the at least one HMG CoA reductase inhibitor is atorvastatin.
31. The composition or therapeutic combination according to claim 28, wherein the at least one HMG CoA reductase inhibitor is rosuvastatin.
32. The composition according to any one of claims 1 to 31, further comprising at least one lipid-lowering agent selected from the group consisting of bile acid sequestrants, nicotinic acid or derivatives thereof, CETP
inhibitors, IBAT
inhibitors, AcylCoA:Cholesterol O-acyltransferase Inhibitors, probucol or derivatives thereof, low-density lipoprotein receptor activators, Omega 3 fatty acids, natural water soluble fibers, plant sterols, plant stanols and fatty acid esters of plant stanols.
inhibitors, IBAT
inhibitors, AcylCoA:Cholesterol O-acyltransferase Inhibitors, probucol or derivatives thereof, low-density lipoprotein receptor activators, Omega 3 fatty acids, natural water soluble fibers, plant sterols, plant stanols and fatty acid esters of plant stanols.
33. The composition according to any one of claims 1 to 32, further comprising at least one additive selected from the group consisting of antioxidants, vitamins, hormone replacement therapy compositions, obesity control medications, blood modifiers, cardiovascular agents different from the compound of Formula II and antidiabetic medications.
34. A therapeutic combination comprising:
(a) a first amount of at least one cholesterol biosynthesis inhibitor;
(b) a second amount of a compound represented by Formula (II) below:
or a pharmaceutically acceptable salt or solvate thereof;
(c) lactose monohydrate;
(d) microcrystalline cellulose;
(e) povidone;
(f) croscarmellose sodium;
(g) sodium lauryl sulfate; and (h) magnesium stearate, wherein the first amount and the second amount together comprise a therapeutically effective amount for the treatment or prevention of a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal.
(a) a first amount of at least one cholesterol biosynthesis inhibitor;
(b) a second amount of a compound represented by Formula (II) below:
or a pharmaceutically acceptable salt or solvate thereof;
(c) lactose monohydrate;
(d) microcrystalline cellulose;
(e) povidone;
(f) croscarmellose sodium;
(g) sodium lauryl sulfate; and (h) magnesium stearate, wherein the first amount and the second amount together comprise a therapeutically effective amount for the treatment or prevention of a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal.
35. The therapeutic combination according to claim 34, wherein the at least one cholesterol biosynthesis inhibitor is in a form for concomitant administration with the compound of Formula (II) or a pharmaceutically acceptable salt or solvate thereof.
36. The therapeutic combination according to claim 34, wherein the at least one cholesterol biosynthesis inhibitor and the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, are present in separate treatment compositions.
37. The therapeutic combination according to any one of claims 34 to 36, wherein the therapeutic combination comprises about 0.1 to about 1000 milligrams of the compound of Formula (II) or a pharmaceutically acceptable salt or solvate thereof.
38. The therapeutic combination according to claim 37, wherein the therapeutic combination comprises about 0.25 to about 50 milligrams of the compound of Formula (II) or a pharmaceutically acceptable salt or solvate thereof.
39. The composition or therapeutic combination according to claim 38, wherein the composition or therapeutic combination comprises about 10 milligrams of the compound of Formula (II) or a pharmaceutically acceptable salt or solvate thereof.
40. The therapeutic combination according to any one of claims 34 to 39, wherein the therapeutic combination comprises about 0.1 to about 90 weight percent of lactose monohydrate based upon total weight of the combination.
41. The therapeutic combination according to claim 40, wherein the therapeutic combination comprises about 55 milligrams of lactose monohydrate.
42. The therapeutic combination according to any one of claims 34 to 41, wherein the therapeutic combination comprises about 0.1 to about 90 weight percent of microcrystalline cellulose based upon total weight of the combination.
43. The therapeutic combination according to claim 42, wherein the therapeutic combination comprises about 20 milligrams of microcrystalline cellulose.
44. The therapeutic combination according to any one of claims 34 to 43, wherein the therapeutic combination comprises about 0.1 to about 90 weight percent of povidone based upon total weight of the combination.
45. The therapeutic combination according to claim 44, wherein the therapeutic combination comprises about 4 milligrams of povidone.
46. The therapeutic combination according to any one of claims 34 to 45, wherein the therapeutic combination comprises about 0.1 to about 90 weight percent of croscarmellose sodium based upon total weight of the combination.
47. The therapeutic combination according to claim 46, wherein the therapeutic combination comprises about 8 milligrams of croscarmellose sodium.
48. The therapeutic combination according to any one of claims 34 to 47, wherein the therapeutic combination comprises about 0.1 to about 90 weight percent of sodium lauryl sulfate based upon total weight of the combination.
49. The therapeutic combination according to claim 48, wherein the therapeutic combination comprises about 2 milligrams of sodium lauryl sulfate.
50. The therapeutic combination according to any one of claims 34 to 49, wherein the therapeutic combination comprises about 0.1 to about 90 weight percent of magnesium stearate based upon total weight of the combination.
51. The therapeutic combination according to claim 50, wherein the therapeutic combination comprises about 1 milligram of magnesium stearate.
52. The therapeutic combination according to any one of claims 1 to 51, wherein the composition or therapeutic combination further comprises at least one peroxisome proliferator-activated receptor activator.
53. The therapeutic combination according to claim 52, wherein the at least one peroxisome proliferator-activated receptor activator is a fabric acid derivative selected from the group consisting of fenofibrate, clofibrate, gemfibrozil, ciprofibrate, bezafibrate, clinofibrate, binifibrate, lifibrol and mixtures thereof.
54. The therapeutic combination according to claim 53, wherein the fabric acid derivative is fenofibrate.
55. The therapeutic combination according to claim 53, wherein the fabric acid derivative is gemfibrozil.
56. The therapeutic combination according to any one of claims 34 to 55, wherein the therapeutic combination further comprises at least one cholesterol biosynthesis inhibitor.
57. The therapeutic combination according to claim 56, wherein the at least one cholesterol biosynthesis inhibitor comprises at least one HMG CoA
reductase inhibitor.
reductase inhibitor.
58. The therapeutic combination according to claim 57, wherein the at least one HMG CoA reductase inhibitor is selected from the group consisting of lovastatin, pravastatin, fluvastatin, simvastatin, atorvastatin, rosuvastatin, cerivastatin and mixtures thereof.
59. The therapeutic combination according to claim 58, wherein the at least one HMG CoA reductase inhibitor is simvastatin.
60. The therapeutic combination according to claim 58, wherein the at least one HMG CoA reductase inhibitor is atorvastatin.
61. The therapeutic combination according to claim 58, wherein the at least one HMG CoA reductase inhibitor is rosuvastatin.
62. The therapeutic combination according to any one of claims 34 to 61, further comprising at least one lipid-lowering agent selected from the group consisting of bile acid sequestrants, nicotinic acid or derivatives thereof, CETP
inhibitors, IBAT inhibitors, AcylCoA:Cholesterol O-acyltransferase Inhibitors, probucol or derivatives thereof, low-density lipoprotein receptor activators, Omega 3 fatty acids, natural water soluble fibers, plant sterols, plant stanols and fatty acid esters of plant stanols.
inhibitors, IBAT inhibitors, AcylCoA:Cholesterol O-acyltransferase Inhibitors, probucol or derivatives thereof, low-density lipoprotein receptor activators, Omega 3 fatty acids, natural water soluble fibers, plant sterols, plant stanols and fatty acid esters of plant stanols.
63. The therapeutic combination according to any one of claims 34 to 62, further comprising at least one additive selected from the group consisting of antioxidants, vitamins, hormone replacement therapy compositions, obesity control medications, blood modifiers, cardiovascular agents different from the compound of Formula II and antidiabetic medications.
64. A pharmaceutical composition comprising a therapeutically effective amount of the composition of any one of claims 1 to 33, in association with a pharmaceutically acceptable carrier.
65. A pharmaceutical composition comprising a therapeutically effective amount of the therapeutic combination of any one of claims 34 to 63, in association with a pharmaceutically acceptable carrier.
66. The composition of any one of claims 1 to 33 for use in treating or preventing a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal.
67. The therapeutic combination of any one of claims 34 to 63, for use in treating or preventing a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal.
68. A composition comprising:
(a) at least one sterol absorption inhibitor selected from the group consisting of:
(1) a sterol absorption inhibitor represented by Formula (I):
or a pharmaceutically acceptable salt or solvate thereof, wherein in Formula (I) above:
Ar1 and Ar2 are independently selected from the group consisting of aryl and R4-substituted aryl;
Ar3 is aryl or R5-substituted aryl;
X, Y and Z are independently selected from the group consisting of -CH2-, -CH(lower alkyl)- and -C(dilower alkyl)-;
R and R2 are independently selected from the group consisting of -OR6, -O(CO)R6, -O(CO)OR9 and -O(CO)NR6R7;
R1 and R3 are independently selected from the group consisting of hydrogen, lower alkyl and aryl;
q is 0 or 1;
r is 0 or 1;
m, n and p are independently selected from 0, 1, 2, 3 or 4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1, 2, 3, 4, 5 or 6; and provided that when p is 0 and r is 1, the sum of m, q and n is 1, 2, 3, 4 or 5;
R4 is 1-5 substituents independently selected from the group consisting of lower alkyl, -OR6, -O(CO)R6, -O(CO)OR9, -O(CH2)1-5OR6, -O(CO)NR6R7, -NR6R7, -NR6(CO)R7, -NR6(CO)OR9, -NR6(CO)NR7R8, -NR6SO2R9, -COOR6, -CONR6R7, -COR6, -SO2NR6R7, S(O)0-2R9, -O(CH2)1-10-COOR6, -O(CH2)1-10CONR6R7, -(lower alkylene)COOR6, -CH=CH-COOR6, -CF3, -CN, -NO2 and halogen;
R5 is 1-5 substituents independently selected from the group consisting of -OR6, -O(CO)R6, -O(CO)OR9, -O(CH2)1-5OR6, -O(CO)NR6R7, -NR6R7, -NR6(CO)R7, -NR6(CO)OR9, -NR6(CO)NR7R8, -NR6SO2R9, -COOR6, -CONR6R7, -COR6, -SO2NR6R7, S(O)0-2R9, -O(CH2)1-10-COOR6, -O(CH2)1-10CONR6R7, -(lower alkylene)COOR6 and -CH=CH-COOR6;
R6, R7 and R8 are independently selected from the group consisting of hydrogen, lower alkyl, aryl and aryl-substituted lower alkyl; and R9 is lower alkyl, aryl or aryl-substituted lower alkyl;
(2) a sterol absorption inhibitor represented by Formula (III):
or a pharmaceutically acceptable salt or solvate thereof, wherein in Formula (III) above:
Ar1 is R3-substituted aryl;
Ar2 is R4-substituted aryl;
Ar3 is R5-substituted aryl;
Y and Z are independently selected from the group consisting of -CH2-, -CH(lower alkyl)- and -C(dilower alkyl)-;
A is selected from -O-, -S-, -S(O)- or -S(O)2-;
R1 is selected from the group consisting of -OR6, -O(CO)R6, -O(CO)OR9 and -O(CO)NR6R7;
R2 is selected from the group consisting of hydrogen, lower alkyl and aryl;
or R1 and R2 together are =O;
q is 1, 2 or 3;
p is 0, 1, 2, 3 or 4;
R5 is 1-3 substituents independently selected from the group consisting of -OR6, -O(CO)R6, -O(CO)OR9, -O(CH2)1-5OR9, -O(CO)NR6R7, -NR6R7, -NR6(CO)R7, -NR6(CO)OR9, -NR6(CO)NR7R8, -NR6SO2-lower alkyl, -NR6S02-aryl, -CONR6R7, -COR6, -SO2NR6R7, S(O)0-2-alkyl, S(O)0-2-aryl, -O(CH2)1-10-COOR6, -O(CH2)1-10CONR6R7, o-halogeno, m-halogeno, o-lower alkyl, m-lower alkyl, -(lower alkylene)-COOR6, and -CH=CH-COOR6;
R3 and R4 are independently 1-3 substituents independently selected from the group consisting of R5, hydrogen, p-lower alkyl, aryl, -NO2, -CF3 and p-halogeno;
R6, R7 and R8 are independently selected from the group consisting of hydrogen, lower alkyl, aryl and aryl-substituted lower alkyl; and R9 is lower alkyl, aryl or aryl-substituted lower alkyl;
(3) a sterol absorption inhibitor represented by Formula (IV):
or a pharmaceutically acceptable salt or solvate thereof, wherein, in Formula (IV) above:
A is selected from the group consisting of R2-substituted heterocycloalkyl, R2-substituted heteroaryl, R2-substituted benzofused heterocycloalkyl, and R2-substituted benzofused heteroaryl;
Ar1 is aryl or R3-substituted aryl;
Ar2 is aryl or R4-substituted aryl;
Q is a bond or, with the 3-position ring carbon of the azetidinone, forms the spiro group and R1 is selected from the group consisting of:
-(CH2)q-, wherein q is 2-6, provided that when Q forms a spiro ring, q can also be zero or 1;
-(CH2)e-G-(CH2)r-, wherein G is -O-, -C(O)-, phenylene, -NR8- or -S(O)0-2-, e is 0-5 and r is 0-5, provided that the sum of e and r is 1-6;
-(C2-C6 alkenylene)-; and -(CH3)f-V-(CH2)g-, wherein V is C3-C6 cycloalkylene, f is 1-5 and g is 0-5, provided that the sum of f and g is 1-6;
R5 is selected from:
R6 and R7 are independently selected from the group consisting of -CH2-, -CH(C1-C6 alkyl)-, -C(di-(C1-C6) alkyl), -CH=CH- and -C(C1-C6 alkyl)=CH-; or R5 together with an adjacent R6, or R5 together with an adjacent R7, form a -CH=CH- or a -CH=C(C1-C6 alkyl)- group;
a and b are independently 0, 1, 2 or 3, provided both are not zero; provided that when R6 is -CH=CH- or -C(C1-C6 alkyl)=CH-, a is l; provided that when R7 is -CH=CH- or -C(C1-C6 alkyl)=CH-, b is 1; provided that when a is 2 or 3, the R6's can be the same or different; and provided that when b is 2 or 3, the R7's can be the same or different;
and when Q is a bond, R1 also can be selected from:
where M is -O-, -S-, -S(O)- or -S(O)2-;
X, Y and Z are independently selected from the group consisting of -CH2-, -CH(C1-C6 alkyl)- and -C(di-(C1-C6) alkyl);
R10 and R12 are independently selected from the group consisting of -OR14, -O(CO)R14, -O(CO)OR16 and -O(CO)NR14R15, R11 and R13 are independently selected from the group consisting of hydrogen, (C1-C6)alkyl and aryl; or R10 and R11 together are =O, or R12 and together are =O;
d is 1, 2 or 3;
h is 0, 1, 2, 3 or 4;
s is 0 or 1; t is 0 or 1; m, n and p are independently 0-4; provided that at least one of s and t is 1, and the sum of m, n, p, s and t is 1-6; provided that when p is 0 and t is 1, the sum of m, s and n is 1-5; and provided that when p is 0 and s is 1, the sum of m, t and n is 1-5;
v is 0 or 1;
j and k are independently 1-5, provided that the sum of j, k and v is 1-5;
R2 is 1-3 substituents on the ring carbon atoms selected from the group consisting of hydrogen, (C1-C10)alkyl, (C2-C10)alkenyl, (C2-C10)alkynyl, (C3-C6)cycloalkyl, (C3-C6)cycloalkenyl, R17-substituted aryl, R17-substituted benzyl, R17-substituted benzyloxy, R17-substituted aryloxy, halogeno, -NR14R15 NR14R15(C1-C6 alkylene)-, NR14R15C(O)(C1-C6 alkylene)-,-NHC(O)R16, OH, C1-C6 alkoxy, -OC(O)R16, -COR14, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl, NO2, -S(O)0-2R16, -SO2NR14R15 and -(C1-C6 alkylene)COOR14; when R2 is a substituent on a heterocycloalkyl ring, R2 is as defined, or is =O or ; and, where R2 is a substituent on a substitutable ring nitrogen, it is hydrogen, (C1-C6)alkyl, aryl, (C1-C6)alkoxy, aryloxy, (C1-C6)alkylcarbonyl, arylcarbonyl, hydroxy, -(CH2)1-6CONR18R18, wherein J is -O-, -NH-, -NR18- or -CH2-;
R3 and R4 are independently selected from the group consisting of 1-3 substituents independently selected from the group consisting of (C1-C6)alkyl, -OR14 -O(CO)R14, -O(CO)OR16, -O(CH2)OR14, -O(CO)NR14R15, -NR14R15, -NR14(CO)R15, -NR14(CO)OR16, -NR14(CO)NR15R19, -NR14SO2R16, -COOR14, -CONR14R15, -COR14, -SO2NR14R15, S(O)0-2R16, -O(CH2)1-10-COOR14, -O(CH2)1-10CONR14R15, -(C1-C6 alkylene)-COOR14, -CH=CH-COOR14, -CF3, -CN, -NO2 and halogen;
R8 is hydrogen, (C1-C6)alkyl, aryl (C1-C6)alkyl, -C(O)R14 or -COOR14, R9 and R17 are independently 1-3 groups independently selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, -COOH, NO2, -NR14R15, OH and halogeno;
R14 and R15 are independently selected from the group consisting of hydrogen, (C1-C6)alkyl, aryl and aryl-substituted (C1-C6)alkyl;
R16 is (C1-C6)alkyl, aryl or R17-substituted aryl;
R18 is hydrogen or (C1-C6)alkyl; and R19 is hydrogen, hydroxy or (C1-C6)alkoxy;
(4) a sterol absorption inhibitor represented by Formula (V):
(5) or a pharmaceutically acceptable salt or solvate thereof, wherein in Formula (V) above:
Ar1 is aryl, R10-substituted aryl or heteroaryl;
Ar2 is aryl or R4-substituted aryl;
Ar3 is aryl or R5-substituted aryl;
X and Y are independently selected from the group consisting of -CH2-, -CH(lower alkyl)- and -C(dilower alkyl)-;
R is -OR6, -O(CO)R6, -O(CO)OR9 or -O(CO)NR6R7; R1 is hydrogen, lower alkyl or aryl; or R and R1 together are =O;
q is 0 or 1;
r is 0, 1 or 2;
m and n are independently 0, 1, 2, 3, 4 or 5; provided that the sum of m, n and q is 1,2,3,4 or 5;
R4 is 1-5 substituents independently selected from the group consisting of lower alkyl, -OR6, -O(CO)R6, -O(CO)OR9, -O(CH2)1-5OR6, -O(CO)NR6R7, -NR6R7, -NR6(CO)R7, -NR6(CO)OR9, -NR6(CO)NR7R8, -NR6SO2R9, -COOR6, -CONR6R7, -COR6, -SO2NR6R7, S(O)0-2R9, -O(CH2)1-10-COOR6, -O(CH2)1-10CONR6R7, -(lower alkylene)COOR6 and -CH=CH-COOR6;
R5 is 1-5 substituents independently selected from the group consisting of -OR6, -O(CO)R6, -O(CO)OR9, -O(CH2)1-5OR6, -O(CO)NR6R7, -NR6R7, -NR6 (CO)R7, -NR6(CO)OR9, -NR6(CO)NR7R8, -NR6SO2R9, -COOR6, -CONR6R7, -COR6, -SO2NR6R7, S(O)0-2R9, -O(CH2)1-10-COOR6, -O(CH2)1-10CONR6R7, -CF3, -CN, -NO2, halogen, -(lower alkylene)COOR6 and -CH=CH-COOR6;
R6, R7 and R8 are independently selected from the group consisting of hydrogen, lower alkyl, aryl and aryl-substituted lower alkyl;
R9 is lower alkyl, aryl or aryl-substituted lower alkyl; and R10 is 1-5 substituents independently selected from the group consisting of lower alkyl, -OR6, -O(CO)R6, -O(CO)OR9, -O(CH2)1-5OR6, -O(CO)NR6R7, -NR6R7, -NR6(CO)R7, -NR6(CO)OR9, -NR6(CO)NR7R8, -NR6SO2R9, -COOR6, -CONR6R7, -COR6, -SO2NR6R7, -S(O)0-2R9, -O(CH2)1-10-COOR6, -O(CH2)1-10CONR6R7, -CF3, -CN, -NO2 and halogen;
(6) a sterol absorption inhibitor represented by Formula (VI):
or a pharmaceutically acceptable salt or solvate thereof, wherein in Formula VI
above:
R1 is -~H-, -C(lower alkyl)-, -~F-, -~(OH)-, -~(C6H5)-, -~(C6H4-R15)-, -~- or -+~O- ;
R2 and R3 are independently selected from the group consisting of:
-CH2-, -CH(lower alkyl)-, -C(di-lower alkyl)-, -CH=CH- and -C(lower alkyl)=CH-; or R1 together with an adjacent R2, or R1 together with an adjacent R3, form a -CH=CH- or a -CH=C(lower alkyl)- group;
u and v are independently 0, 1, 2 or 3, provided both are not zero; provided that when R2 is -CH=CH- or -C(lower alkyl)=CH-, v is 1; provided that when R3 is -CH=CH- or -C(lower alkyl)=CH-, u is 1; provided that when v is 2 or 3, the R2's can be the same or different; and provided that when a is 2 or 3, the R3's can be the same or different;
R4 is selected from B-(CH2)m C(O)-, wherein m is 0, 1, 2, 3, 4 or 5;
B-(CH2)q-, wherein q is 0, 1, 2, 3, 4, 5 or 6;
B-(CH2)e-Z-(CH2)r-, wherein Z is -O-, -C(O)-, phenylene, -N(R8)- or -S(O)0-2-, e is 0, 1, 2, 3, 4 or 5 and r is 0, 1, 2, 3, 4 or 5, provided that the sum of e and r is 0, 1, 2, 3, 4, 5 or 6;
B-(C2-C6 alkenylene)-;
B-(C4-C6 alkadienylene)-;
B-(CH2)t-Z-(C2-C6 alkenylene)-, wherein Z is as defined above, and wherein t is 0, 1, 2 or 3, provided that the sum of t and the number of carbon atoms in the alkenylene chain is 2, 3, 4, 5 or 6;
B-(CH2)f-V-(CH2)g-, wherein V is C3-C6 cycloalkylene, f is 1, 2, 3, 4 or 5 and g is 0, 1, 2, 3, 4 or 5, provided that the sum of f and g is 1, 2, 3, 4, 5 or 6;
B-(CH2)t-V-(C2-C6 alkenylene)- or B-(C2-C6 alkenylene)-V-(CH2)t-, wherein V and t are as defined above, provided that the sum of t and the number of carbon atoms in the alkenylene chain is 2, 3, 4, or 6;
B-(CH2)a-Z-(CH2)b-V-(CH2)d-, wherein Z and V are as defined above and a, b and d are independently 0, 1, 2, 3, 4, 5 or 6, provided that the sum of a, b and d is 0, 1, 2, 3, 4, 5 or 6; or T-(CH2)s-, wherein T is cycloalkyl of 3-6 carbon atoms and s is 0, 1, 2, 3, 4, 5 or 6; or R1 and R4 together form the group B-CH=~- ;
B is selected from indanyl, indenyl, naphthyl, tetrahydronaphthyl, heteroaryl or W-substituted heteroaryl, wherein heteroaryl is selected from the group consisting of pyrrolyl, pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, imidazolyl, thiazolyl, pyrazolyl, thienyl, oxazolyl and furanyl, and for nitrogen-containing heteroaryls, the N-oxides thereof, or W is 1 to 3 substituents independently selected from the group consisting of lower alkyl, hydroxy lower alkyl, lower alkoxy, alkoxyalkyl, alkoxyalkoxy, alkoxycarbonylalkoxy, (lower alkoxyimino)-lower alkyl, lower alkanedioyl, lower alkyl lower alkanedioyl, allyloxy, -CF3, -OCF3, benzyl, R7-benzyl, benzyloxy, R7-benzyloxy, phenoxy, R7-phenoxy, dioxolanyl, NO2, -N(R8)(R9), N(R8)(R9)-lower alkylene-, N(R8)(R9)-lower alkylenyloxy-, OH, halogeno, -CN, -N3, -NHC(O)OR10, -NHC(O)R10, R11O2SNH-, (R11O2S)2N-, -S(O)2NH2, -S(O)0-2R8, tert-butyldimethyl-silyloxymethyl, -C(O)R12, -COOR19, -CON(R8)(R9), -CH=CHC(O)R12, -lower alkylene-C(O)R12, R10C(O)(lower alkylenyloxy)-, N(R8)(R9)C(O)(lower alkylenyloxy)- and for substitution on ring carbon atoms, and the substituents on the substituted heteroaryl ring nitrogen atoms, when present, are selected from the group consisting of lower alkyl, lower alkoxy, -C(O)OR10, -C(O)R10, OH, N(R8)(R9)-lower alkylene-,N(R8)(R9)-lower alkylenyloxy-, -S(O)2NH2 and 2-(trimethylsilyl)-ethoxymethyl;
R7 is 1-3 groups independently selected from the group consisting of lower alkyl, lower alkoxy, -COOH, NO2, -N(R8)(R9), OH, and halogeno;
R8 and R9 are independently selected from H or lower alkyl;
R10 is selected from lower alkyl, phenyl, R7-phenyl, benzyl or R7-benzyl;
R11 is selected from OH, lower alkyl, phenyl, benzyl, R7-phenyl or R7-benzyl;
R12 is selected from H, OH, alkoxy, phenoxy, benzyloxy, , -N(R8)(R9), lower alkyl, phenyl or R7-phenyl;
R13 is selected from -O-, -CH2-, -NH-, -N(lower alkyl)- or -NC(O)R19;
R15, R16 and R17 are independently selected from the group consisting of H and the groups defined for W; or R15 is hydrogen and R16 and R17, together with adjacent carbon atoms to which they are attached, form a dioxolanyl ring;
R19 is H, lower alkyl, phenyl or phenyl lower alkyl; and R20 and R21 are independently selected from the group consisting of phenyl, W-substituted phenyl, naphthyl, W-substituted naphthyl, indanyl, indenyl, tetrahydronaphthyl, benzodioxolyl, heteroaryl, W-substituted heteroaryl, benzofused heteroaryl, W-substituted benzofused heteroaryl and cyclopropyl, wherein heteroaryl is as defined above;
(8) a sterol absorption inhibitor represented by Formula (VII):
(9) or a pharmaceutically acceptable salt or solvate thereof, wherein in Formula (VII):
A is -CH=CH-, -C.ident.C- or -(CH2)p- wherein p is 0, 1 or 2;
B is E is C10 to C20 alkyl or -C(O)-(C9 to C19)-alkyl, wherein the alkyl is straight or branched, saturated or containing one or more double bonds;
R is hydrogen, C1-C15 alkyl, straight or branched, saturated or containing one or more double bonds, or B-(CH2)r-, wherein r is 0, 1, 2, or 3;
R1, R2, and R3 are independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, carboxy, NO2, NH2, OH, halogeno, lower alkylamino, dilower alkylamino, -NHC(O)OR5, R6O2SNH- and -S(O)2NH2;
R4 is wherein n is 0, 1, 2 or 3;
R5 is lower alkyl; and R6 is OH, lower alkyl, phenyl, benzyl or substituted phenyl wherein the substituents are 1-3 groups independently selected from the group consisting of lower alkyl, lower alkoxy, carboxy, NO2, NH2, OH, halogeno, lower alkylamino and dilower alkylamino;
(10) a sterol absorption inhibitor represented by Formula (VIII):
(11) or a pharmaceutically acceptable salt or solvate thereof, wherein in Formula (VIII) above:
R26 is H or OG1;
G and G1 are independently selected from the group consisting of ; provided that when R26 is H or OH, G is not H;
R, R a and R b are independently selected from the group consisting of H, -OH, halogeno, -NH2, azido, (C1-C6)alkoxy(C1-C6)-alkoxy or -W-R30;
W is independently selected from the group consisting of -NH-C(O)-, -O-C(O)-, -O-C(O)-N(R31)-, -NH-C(O)-N(R31)- and -O-C(S)-N(R31)-;
R2 and R6 are independently selected from the group consisting of H, (C1-C6)alkyl, aryl and aryl(C1-C6)alkyl;
R3, R4, R5, R7, R3a and R4a are independently selected from the group consisting of H, (C1-C6)alkyl, aryl(C1-C6)alkyl, -C(O)(C1-C6)alkyl and -C(O) aryl;
R30 is selected from the group consisting of R32-substituted T, R32-substituted-T-(C1-C6)alkyl, R32-substituted-(C2-C4)alkenyl, R32-substituted-(C1-C6)alkyl, R32-substituted-(C3-C7)cycloalkyl and R32-substituted-(C3-C7)cycloalkyl(C1-C6)alkyl;
R31 is selected from the group consisting of H and (C1-C4)alkyl;
T is selected from the group consisting of phenyl, furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, iosthiazolyl, benzothiazolyl, thiadiazolyl, pyrazolyl, imidazolyl and pyridyl;
R32 is independently selected from 1-3 substituents independently selected from the group consisting of halogeno, (C1-C4)alkyl, -OH, phenoxy, -CF3, -NO2, (C1-C4)alkoxy, methylenedioxy, oxo, (C1-C4)alkylsulfanyl, (C1-C4)alkylsulfinyl, (C1-C4)alkylsulfonyl, -N(CH3)2, -C(O)-NH(C1-C4)alkyl, -C(O)-N((C1-C4)alkyl)2, -C(O)-(C1-C4)alkyl, -C(O)-(C1-C4)alkoxy and pyrrolidinylcarbonyl; or R32 is a covalent bond and R31, the nitrogen to which it is attached and R32 form a pyrrolidinyl, piperidinyl, N-methyl-piperazinyl, indolinyl or morpholinyl group, or a (C1-C4)alkoxycarbonyl-substituted pyrrolidinyl, piperidinyl, N-methylpiperazinyl, indolinyl or morpholinyl group;
Ar1 is aryl or R10-substituted aryl;
Ar2 is aryl or R11-substituted aryl;
Q is a bond or, with the 3-position ring carbon of the azetidinone, forms the spiro group ; and R1 is selected from the group consisting of -(CH2)q-, wherein q is 2-6, provided that when Q forms a spiro ring, q can also be zero or 1;
-(CH2)e-E-(CH2)r-, wherein E is -O-, -C(O)-, phenylene, -NR22- or -S(O)0-2-, e is 0-5 and r is 0-5, provided that the sum of e and r is 1-6;
-(C2-C6)alkenylene-; and -(CH2)-f-V-(CH2)g-, wherein V is C3-C6 cycloalkylene, f is 1-5 and g is 0-5, provided that the sum of f and g is 1-6;
R12 is R13 and R14 are independently selected from the group consisting of -CH2-, -CH(C1-C6 alkyl)-, -C(di-(C1-C6) alkyl), -CH=CH- and -C(C1-C6 alkyl)=CH-; or R12 together with an adjacent R13, or R12 together with an adjacent R14, form a -CH=CH- or a -CH=C(C1-C6 alkyl)- group;
a and b are independently 0, 1, 2 or 3, provided both are not zero;
provided that when R13 is -CH=CH- or -C(C1-C6 alkyl)=CH-, a is 1;
provided that when R14 is -CH=CH- or -C(C1-C6 alkyl)=CH-, b is 1;
provided that when a is 2 or 3, the R13's can be the same or different; and provided that when b is 2 or 3, the R14's can be the same or different;
and when Q is a bond, R1 also can be:
M is -O-, -S-, -S(O)- or -S(O)2-;
X, Y and Z are independently selected from the group consisting of -CH2-, -CH(C1-C6)alkyl- and -C(di-(C1-C6)alkyl);
R10 and R11 are independently selected from the group consisting of 1-3 substituents independently selected from the group consisting of (C1-C6)alkyl, -OR19, -O(CO)R19, -O(CO)OR21, -O(CH2)1-5OR19, -O(CO)NR19R20, -NR19R20, -NR19(CO)R20, -NR19(CO)OR21, -NR19(CO)NR20R25, -NR19SO2R21, -COOR19, -CONR19R20, -COR19, -SO2NR19R20, S(O)0-2R21, -O(CH2)1-10-COOR19, -O(CH2)1-10CONR19R20, -(C1-C6 alkylene)-COOR19, -CH=CH-COOR19, -CF3, -CN, -NO2 and halogen;
R15 and R17 are independently selected from the group consisting of -OR19, -O(CO)R19, -O(CO)OR21 and -O(CO)NR19R20;
R16 and R18 are independently selected from the group consisting of H, (C1-C6)alkyl and aryl; or R15 and R16 together are =O, or R17 and R18 together are =O;
d is 1, 2 or 3;
h is 0, 1, 2, 3 or 4;
s is 0 or 1; t is 0 or 1; m, n and p are independently 0-4;
provided that at least one of s and t is 1, and the sum of m, n, p, s and t is 6;
provided that when p is 0 and t is 1, the sum of m, s and n is 1-5; and provided that when p is 0 and s is 1, the sum of m, t and n is 1-5;
v is 0 or 1;
j and k are independently 1-5, provided that the sum of j, k and v is 1-5;
and when Q is a bond and R1 is , Ar1 can also be ~
pyridyl, isoxazolyl, furanyl, pyrrolyl, thienyl, imidazolyl, pyrazolyl, thiazolyl, pyrazinyl, pyrimidinyl or pyridazinyl;
R19 and R20 are independently selected from the group consisting of H, (C1-C6)alkyl, aryl and aryl-substituted (C1-C6)alkyl;
R21 is (C1-C6)alkyl, aryl or R24-substituted aryl;
R22 is H, (C1-C6)alkyl, aryl (C1-C6)alkyl, -C(O)R19 or -COOR19;
R23 and R24 are independently 1-3 groups independently selected from the group consisting of H, (C1-C6)alkyl, (C1-C6)alkoxy, -COOH, NO2, -NR19R20, -OH and halogeno; and R25 is H, -OH or (C1-C6)alkoxy; and (12) a sterol absorption inhibitor represented by Formula (IX):
(13) or a pharmaceutically acceptable salt or solvate thereof, wherein, in Formula (IX) above, R26 is selected from the group consisting of:
a) OH;
b) OCH3;
c) fluorine and d) chlorine;
R1 is selected from the group consisting of -SO3H; natural and unnatural amino acids;
R, R a and R b are independently selected from the group consisting of H, -OH, halogeno, -NH2, azido, (C1-C6)alkoxy(C1-C6)-alkoxy and -W-R30;
W is independently selected from the group consisting of -NH-C(O)-, -O-C(O)-, -O-C(O)-N(R31)-, -NH-C(O)-N(R31)- and -O-C(S)-N(R31)-;
R2 and R6 are independently selected from the group consisting of H, (C1-C6)alkyl, aryl and aryl(C1-C6)alkyl;
R3, R4, R5, R7, R3a and R4a are independently selected from the group consisting of H, (C1-C6)alkyl, aryl(C1-C6)alkyl, -C(O)(C1-C6)alkyl and -C(O)aryl;
R30 is independently selected form the group consisting of R32-substituted T, R32-substituted-T-(C1-C6)alkyl, R32-substituted-(C2-C4)alkenyl, R32-substituted-(C1-C6)alkyl, R32-substituted-(C3-C7)cycloalkyl and R32-substituted-(C3-C7)cycloalkyl(C1-C6)alkyl;
R31 is independently selected from the group consisting of H and (C1-C4)alkyl;
T is independently selected from the group consisting of phenyl, furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, iosthiazolyl, benzothiazolyl;
thiadiazolyl, pyrazolyl, imidazolyl and pyridyl;
R32 is independently selected from 1-3 substituents independently selected from the group consisting of H, halogeno, (C1-C4)alkyl, -OH, phenoxy, -CF3, -NO2, (C1-C4)alkoxy, methylenedioxy, oxo, (C1-C4)alkylsulfanyl, (C1-C4)alkylsulfinyl, (C1-C4)alkylsulfonyl, -N(CH3)2, -C(O)-NH(C1-C4)alkyl, -C(O)-N((C1-C4)alkyl)2, -C(O)-(C1-C4)alkyl, -C(O)-(C1-C4)alkoxy and pyrrolidinylcarbonyl; or R32 is a covalent bond and R31, the nitrogen to which it is attached and R32 form a pyrrolidinyl, piperidinyl, N-methyl-piperazinyl, indolinyl or morpholinyl group, or a (C1-C4)alkoxycarbonyl-substituted pyrrolidinyl, piperidinyl, N-methylpiperazinyl, indolinyl or morpholinyl group;
Ar1 is aryl, R10-substituted aryl; pyridyl, isoxazolyl, furanyl, pyrrolyl, thienyl, imidazolyl, pyrazolyl, thiazolyl, pyrazinyl, pyrimidinyl or pyridazinyl;
Ar2 is aryl or R11-substituted aryl;
Q is -(CH2)q-, wherein q is 2-6, or, with the 3-position ring carbon of the azetidinone, forms the spiro group ;
R12 is R13 and R14 are independently selected from the group consisting of -CH2-, -CH(C1-C6 alkyl)-, -C(di-(C1-C6) alkyl), -CH=CH- and -C(C1-C6 alkyl)=CH-;
or R12 together with an adjacent R13, or R12 together with an adjacent R14, form a -CH=CH- or a -CH=C(C1-C6 alkyl)- group;
a and b are independently 0, 1, 2 or 3, provided both are not zero; provided that when R13 is -CH=CH- or -C(C1-C6 alkyl)=CH-, a is 1; provided that when R14 is -CH=CH- or -C(C1-C6 alkyl)=CH-, b is 1; provided that when a is 2 or 3, the R13's can be the same or different; and provided that when b is 2 or 3, the R14's can be the same or different;
R10 and R11 are independently selected from the group consisting of 1-3 substituents independently selected from the group consisting of (C1-C6)alkyl, -OR19, -O(CO)R19, -O(CO)OR21, -O(CH2)1-5OR19, -O(CO)NR19R20, -NR19R20, -NR19(CO)R20, -NR19(CO)OR21, -NR19(CO)NR20R25, -NR19SO2R21, -COOR19, -CONR19R20, -COR19, -SO2NR19R20, -S(O)0-2R21, -O(CH2)1-10-COOR19, -O(CH2)1-10CONR19R20, -(C1-C6 alkylene)-COOR19, -CH=CH-COOR19, -CF3, -CN, -NO2 and halogen;
R19 and R20 are independently selected from the group consisting of H, (C1-C6)alkyl, aryl and aryl-substituted (C1-C6)alkyl;
R21 is (C1-C6)alkyl, aryl or R24-substituted aryl;
R22 is H, (C1-C6)alkyl, aryl (C1-C6)alkyl, -C(O)R19 or -COOR19;
R23 and R24 are independently 1-3 groups independently selected from the group consisting of H, (C1-C6)alkyl, (C1-C6)alkoxy, -COOH, NO2, -NR19R20, -OH and halogeno; and R25 is H, -OH or (C1-C6)alkoxy;
(b) lactose monohydrate;
(c) microcrystalline cellulose;
(d) povidone;
(e) croscarmellose sodium;
(f) sodium lauryl sulfate; and (g) magnesium stearate.
(a) at least one sterol absorption inhibitor selected from the group consisting of:
(1) a sterol absorption inhibitor represented by Formula (I):
or a pharmaceutically acceptable salt or solvate thereof, wherein in Formula (I) above:
Ar1 and Ar2 are independently selected from the group consisting of aryl and R4-substituted aryl;
Ar3 is aryl or R5-substituted aryl;
X, Y and Z are independently selected from the group consisting of -CH2-, -CH(lower alkyl)- and -C(dilower alkyl)-;
R and R2 are independently selected from the group consisting of -OR6, -O(CO)R6, -O(CO)OR9 and -O(CO)NR6R7;
R1 and R3 are independently selected from the group consisting of hydrogen, lower alkyl and aryl;
q is 0 or 1;
r is 0 or 1;
m, n and p are independently selected from 0, 1, 2, 3 or 4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1, 2, 3, 4, 5 or 6; and provided that when p is 0 and r is 1, the sum of m, q and n is 1, 2, 3, 4 or 5;
R4 is 1-5 substituents independently selected from the group consisting of lower alkyl, -OR6, -O(CO)R6, -O(CO)OR9, -O(CH2)1-5OR6, -O(CO)NR6R7, -NR6R7, -NR6(CO)R7, -NR6(CO)OR9, -NR6(CO)NR7R8, -NR6SO2R9, -COOR6, -CONR6R7, -COR6, -SO2NR6R7, S(O)0-2R9, -O(CH2)1-10-COOR6, -O(CH2)1-10CONR6R7, -(lower alkylene)COOR6, -CH=CH-COOR6, -CF3, -CN, -NO2 and halogen;
R5 is 1-5 substituents independently selected from the group consisting of -OR6, -O(CO)R6, -O(CO)OR9, -O(CH2)1-5OR6, -O(CO)NR6R7, -NR6R7, -NR6(CO)R7, -NR6(CO)OR9, -NR6(CO)NR7R8, -NR6SO2R9, -COOR6, -CONR6R7, -COR6, -SO2NR6R7, S(O)0-2R9, -O(CH2)1-10-COOR6, -O(CH2)1-10CONR6R7, -(lower alkylene)COOR6 and -CH=CH-COOR6;
R6, R7 and R8 are independently selected from the group consisting of hydrogen, lower alkyl, aryl and aryl-substituted lower alkyl; and R9 is lower alkyl, aryl or aryl-substituted lower alkyl;
(2) a sterol absorption inhibitor represented by Formula (III):
or a pharmaceutically acceptable salt or solvate thereof, wherein in Formula (III) above:
Ar1 is R3-substituted aryl;
Ar2 is R4-substituted aryl;
Ar3 is R5-substituted aryl;
Y and Z are independently selected from the group consisting of -CH2-, -CH(lower alkyl)- and -C(dilower alkyl)-;
A is selected from -O-, -S-, -S(O)- or -S(O)2-;
R1 is selected from the group consisting of -OR6, -O(CO)R6, -O(CO)OR9 and -O(CO)NR6R7;
R2 is selected from the group consisting of hydrogen, lower alkyl and aryl;
or R1 and R2 together are =O;
q is 1, 2 or 3;
p is 0, 1, 2, 3 or 4;
R5 is 1-3 substituents independently selected from the group consisting of -OR6, -O(CO)R6, -O(CO)OR9, -O(CH2)1-5OR9, -O(CO)NR6R7, -NR6R7, -NR6(CO)R7, -NR6(CO)OR9, -NR6(CO)NR7R8, -NR6SO2-lower alkyl, -NR6S02-aryl, -CONR6R7, -COR6, -SO2NR6R7, S(O)0-2-alkyl, S(O)0-2-aryl, -O(CH2)1-10-COOR6, -O(CH2)1-10CONR6R7, o-halogeno, m-halogeno, o-lower alkyl, m-lower alkyl, -(lower alkylene)-COOR6, and -CH=CH-COOR6;
R3 and R4 are independently 1-3 substituents independently selected from the group consisting of R5, hydrogen, p-lower alkyl, aryl, -NO2, -CF3 and p-halogeno;
R6, R7 and R8 are independently selected from the group consisting of hydrogen, lower alkyl, aryl and aryl-substituted lower alkyl; and R9 is lower alkyl, aryl or aryl-substituted lower alkyl;
(3) a sterol absorption inhibitor represented by Formula (IV):
or a pharmaceutically acceptable salt or solvate thereof, wherein, in Formula (IV) above:
A is selected from the group consisting of R2-substituted heterocycloalkyl, R2-substituted heteroaryl, R2-substituted benzofused heterocycloalkyl, and R2-substituted benzofused heteroaryl;
Ar1 is aryl or R3-substituted aryl;
Ar2 is aryl or R4-substituted aryl;
Q is a bond or, with the 3-position ring carbon of the azetidinone, forms the spiro group and R1 is selected from the group consisting of:
-(CH2)q-, wherein q is 2-6, provided that when Q forms a spiro ring, q can also be zero or 1;
-(CH2)e-G-(CH2)r-, wherein G is -O-, -C(O)-, phenylene, -NR8- or -S(O)0-2-, e is 0-5 and r is 0-5, provided that the sum of e and r is 1-6;
-(C2-C6 alkenylene)-; and -(CH3)f-V-(CH2)g-, wherein V is C3-C6 cycloalkylene, f is 1-5 and g is 0-5, provided that the sum of f and g is 1-6;
R5 is selected from:
R6 and R7 are independently selected from the group consisting of -CH2-, -CH(C1-C6 alkyl)-, -C(di-(C1-C6) alkyl), -CH=CH- and -C(C1-C6 alkyl)=CH-; or R5 together with an adjacent R6, or R5 together with an adjacent R7, form a -CH=CH- or a -CH=C(C1-C6 alkyl)- group;
a and b are independently 0, 1, 2 or 3, provided both are not zero; provided that when R6 is -CH=CH- or -C(C1-C6 alkyl)=CH-, a is l; provided that when R7 is -CH=CH- or -C(C1-C6 alkyl)=CH-, b is 1; provided that when a is 2 or 3, the R6's can be the same or different; and provided that when b is 2 or 3, the R7's can be the same or different;
and when Q is a bond, R1 also can be selected from:
where M is -O-, -S-, -S(O)- or -S(O)2-;
X, Y and Z are independently selected from the group consisting of -CH2-, -CH(C1-C6 alkyl)- and -C(di-(C1-C6) alkyl);
R10 and R12 are independently selected from the group consisting of -OR14, -O(CO)R14, -O(CO)OR16 and -O(CO)NR14R15, R11 and R13 are independently selected from the group consisting of hydrogen, (C1-C6)alkyl and aryl; or R10 and R11 together are =O, or R12 and together are =O;
d is 1, 2 or 3;
h is 0, 1, 2, 3 or 4;
s is 0 or 1; t is 0 or 1; m, n and p are independently 0-4; provided that at least one of s and t is 1, and the sum of m, n, p, s and t is 1-6; provided that when p is 0 and t is 1, the sum of m, s and n is 1-5; and provided that when p is 0 and s is 1, the sum of m, t and n is 1-5;
v is 0 or 1;
j and k are independently 1-5, provided that the sum of j, k and v is 1-5;
R2 is 1-3 substituents on the ring carbon atoms selected from the group consisting of hydrogen, (C1-C10)alkyl, (C2-C10)alkenyl, (C2-C10)alkynyl, (C3-C6)cycloalkyl, (C3-C6)cycloalkenyl, R17-substituted aryl, R17-substituted benzyl, R17-substituted benzyloxy, R17-substituted aryloxy, halogeno, -NR14R15 NR14R15(C1-C6 alkylene)-, NR14R15C(O)(C1-C6 alkylene)-,-NHC(O)R16, OH, C1-C6 alkoxy, -OC(O)R16, -COR14, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl, NO2, -S(O)0-2R16, -SO2NR14R15 and -(C1-C6 alkylene)COOR14; when R2 is a substituent on a heterocycloalkyl ring, R2 is as defined, or is =O or ; and, where R2 is a substituent on a substitutable ring nitrogen, it is hydrogen, (C1-C6)alkyl, aryl, (C1-C6)alkoxy, aryloxy, (C1-C6)alkylcarbonyl, arylcarbonyl, hydroxy, -(CH2)1-6CONR18R18, wherein J is -O-, -NH-, -NR18- or -CH2-;
R3 and R4 are independently selected from the group consisting of 1-3 substituents independently selected from the group consisting of (C1-C6)alkyl, -OR14 -O(CO)R14, -O(CO)OR16, -O(CH2)OR14, -O(CO)NR14R15, -NR14R15, -NR14(CO)R15, -NR14(CO)OR16, -NR14(CO)NR15R19, -NR14SO2R16, -COOR14, -CONR14R15, -COR14, -SO2NR14R15, S(O)0-2R16, -O(CH2)1-10-COOR14, -O(CH2)1-10CONR14R15, -(C1-C6 alkylene)-COOR14, -CH=CH-COOR14, -CF3, -CN, -NO2 and halogen;
R8 is hydrogen, (C1-C6)alkyl, aryl (C1-C6)alkyl, -C(O)R14 or -COOR14, R9 and R17 are independently 1-3 groups independently selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, -COOH, NO2, -NR14R15, OH and halogeno;
R14 and R15 are independently selected from the group consisting of hydrogen, (C1-C6)alkyl, aryl and aryl-substituted (C1-C6)alkyl;
R16 is (C1-C6)alkyl, aryl or R17-substituted aryl;
R18 is hydrogen or (C1-C6)alkyl; and R19 is hydrogen, hydroxy or (C1-C6)alkoxy;
(4) a sterol absorption inhibitor represented by Formula (V):
(5) or a pharmaceutically acceptable salt or solvate thereof, wherein in Formula (V) above:
Ar1 is aryl, R10-substituted aryl or heteroaryl;
Ar2 is aryl or R4-substituted aryl;
Ar3 is aryl or R5-substituted aryl;
X and Y are independently selected from the group consisting of -CH2-, -CH(lower alkyl)- and -C(dilower alkyl)-;
R is -OR6, -O(CO)R6, -O(CO)OR9 or -O(CO)NR6R7; R1 is hydrogen, lower alkyl or aryl; or R and R1 together are =O;
q is 0 or 1;
r is 0, 1 or 2;
m and n are independently 0, 1, 2, 3, 4 or 5; provided that the sum of m, n and q is 1,2,3,4 or 5;
R4 is 1-5 substituents independently selected from the group consisting of lower alkyl, -OR6, -O(CO)R6, -O(CO)OR9, -O(CH2)1-5OR6, -O(CO)NR6R7, -NR6R7, -NR6(CO)R7, -NR6(CO)OR9, -NR6(CO)NR7R8, -NR6SO2R9, -COOR6, -CONR6R7, -COR6, -SO2NR6R7, S(O)0-2R9, -O(CH2)1-10-COOR6, -O(CH2)1-10CONR6R7, -(lower alkylene)COOR6 and -CH=CH-COOR6;
R5 is 1-5 substituents independently selected from the group consisting of -OR6, -O(CO)R6, -O(CO)OR9, -O(CH2)1-5OR6, -O(CO)NR6R7, -NR6R7, -NR6 (CO)R7, -NR6(CO)OR9, -NR6(CO)NR7R8, -NR6SO2R9, -COOR6, -CONR6R7, -COR6, -SO2NR6R7, S(O)0-2R9, -O(CH2)1-10-COOR6, -O(CH2)1-10CONR6R7, -CF3, -CN, -NO2, halogen, -(lower alkylene)COOR6 and -CH=CH-COOR6;
R6, R7 and R8 are independently selected from the group consisting of hydrogen, lower alkyl, aryl and aryl-substituted lower alkyl;
R9 is lower alkyl, aryl or aryl-substituted lower alkyl; and R10 is 1-5 substituents independently selected from the group consisting of lower alkyl, -OR6, -O(CO)R6, -O(CO)OR9, -O(CH2)1-5OR6, -O(CO)NR6R7, -NR6R7, -NR6(CO)R7, -NR6(CO)OR9, -NR6(CO)NR7R8, -NR6SO2R9, -COOR6, -CONR6R7, -COR6, -SO2NR6R7, -S(O)0-2R9, -O(CH2)1-10-COOR6, -O(CH2)1-10CONR6R7, -CF3, -CN, -NO2 and halogen;
(6) a sterol absorption inhibitor represented by Formula (VI):
or a pharmaceutically acceptable salt or solvate thereof, wherein in Formula VI
above:
R1 is -~H-, -C(lower alkyl)-, -~F-, -~(OH)-, -~(C6H5)-, -~(C6H4-R15)-, -~- or -+~O- ;
R2 and R3 are independently selected from the group consisting of:
-CH2-, -CH(lower alkyl)-, -C(di-lower alkyl)-, -CH=CH- and -C(lower alkyl)=CH-; or R1 together with an adjacent R2, or R1 together with an adjacent R3, form a -CH=CH- or a -CH=C(lower alkyl)- group;
u and v are independently 0, 1, 2 or 3, provided both are not zero; provided that when R2 is -CH=CH- or -C(lower alkyl)=CH-, v is 1; provided that when R3 is -CH=CH- or -C(lower alkyl)=CH-, u is 1; provided that when v is 2 or 3, the R2's can be the same or different; and provided that when a is 2 or 3, the R3's can be the same or different;
R4 is selected from B-(CH2)m C(O)-, wherein m is 0, 1, 2, 3, 4 or 5;
B-(CH2)q-, wherein q is 0, 1, 2, 3, 4, 5 or 6;
B-(CH2)e-Z-(CH2)r-, wherein Z is -O-, -C(O)-, phenylene, -N(R8)- or -S(O)0-2-, e is 0, 1, 2, 3, 4 or 5 and r is 0, 1, 2, 3, 4 or 5, provided that the sum of e and r is 0, 1, 2, 3, 4, 5 or 6;
B-(C2-C6 alkenylene)-;
B-(C4-C6 alkadienylene)-;
B-(CH2)t-Z-(C2-C6 alkenylene)-, wherein Z is as defined above, and wherein t is 0, 1, 2 or 3, provided that the sum of t and the number of carbon atoms in the alkenylene chain is 2, 3, 4, 5 or 6;
B-(CH2)f-V-(CH2)g-, wherein V is C3-C6 cycloalkylene, f is 1, 2, 3, 4 or 5 and g is 0, 1, 2, 3, 4 or 5, provided that the sum of f and g is 1, 2, 3, 4, 5 or 6;
B-(CH2)t-V-(C2-C6 alkenylene)- or B-(C2-C6 alkenylene)-V-(CH2)t-, wherein V and t are as defined above, provided that the sum of t and the number of carbon atoms in the alkenylene chain is 2, 3, 4, or 6;
B-(CH2)a-Z-(CH2)b-V-(CH2)d-, wherein Z and V are as defined above and a, b and d are independently 0, 1, 2, 3, 4, 5 or 6, provided that the sum of a, b and d is 0, 1, 2, 3, 4, 5 or 6; or T-(CH2)s-, wherein T is cycloalkyl of 3-6 carbon atoms and s is 0, 1, 2, 3, 4, 5 or 6; or R1 and R4 together form the group B-CH=~- ;
B is selected from indanyl, indenyl, naphthyl, tetrahydronaphthyl, heteroaryl or W-substituted heteroaryl, wherein heteroaryl is selected from the group consisting of pyrrolyl, pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, imidazolyl, thiazolyl, pyrazolyl, thienyl, oxazolyl and furanyl, and for nitrogen-containing heteroaryls, the N-oxides thereof, or W is 1 to 3 substituents independently selected from the group consisting of lower alkyl, hydroxy lower alkyl, lower alkoxy, alkoxyalkyl, alkoxyalkoxy, alkoxycarbonylalkoxy, (lower alkoxyimino)-lower alkyl, lower alkanedioyl, lower alkyl lower alkanedioyl, allyloxy, -CF3, -OCF3, benzyl, R7-benzyl, benzyloxy, R7-benzyloxy, phenoxy, R7-phenoxy, dioxolanyl, NO2, -N(R8)(R9), N(R8)(R9)-lower alkylene-, N(R8)(R9)-lower alkylenyloxy-, OH, halogeno, -CN, -N3, -NHC(O)OR10, -NHC(O)R10, R11O2SNH-, (R11O2S)2N-, -S(O)2NH2, -S(O)0-2R8, tert-butyldimethyl-silyloxymethyl, -C(O)R12, -COOR19, -CON(R8)(R9), -CH=CHC(O)R12, -lower alkylene-C(O)R12, R10C(O)(lower alkylenyloxy)-, N(R8)(R9)C(O)(lower alkylenyloxy)- and for substitution on ring carbon atoms, and the substituents on the substituted heteroaryl ring nitrogen atoms, when present, are selected from the group consisting of lower alkyl, lower alkoxy, -C(O)OR10, -C(O)R10, OH, N(R8)(R9)-lower alkylene-,N(R8)(R9)-lower alkylenyloxy-, -S(O)2NH2 and 2-(trimethylsilyl)-ethoxymethyl;
R7 is 1-3 groups independently selected from the group consisting of lower alkyl, lower alkoxy, -COOH, NO2, -N(R8)(R9), OH, and halogeno;
R8 and R9 are independently selected from H or lower alkyl;
R10 is selected from lower alkyl, phenyl, R7-phenyl, benzyl or R7-benzyl;
R11 is selected from OH, lower alkyl, phenyl, benzyl, R7-phenyl or R7-benzyl;
R12 is selected from H, OH, alkoxy, phenoxy, benzyloxy, , -N(R8)(R9), lower alkyl, phenyl or R7-phenyl;
R13 is selected from -O-, -CH2-, -NH-, -N(lower alkyl)- or -NC(O)R19;
R15, R16 and R17 are independently selected from the group consisting of H and the groups defined for W; or R15 is hydrogen and R16 and R17, together with adjacent carbon atoms to which they are attached, form a dioxolanyl ring;
R19 is H, lower alkyl, phenyl or phenyl lower alkyl; and R20 and R21 are independently selected from the group consisting of phenyl, W-substituted phenyl, naphthyl, W-substituted naphthyl, indanyl, indenyl, tetrahydronaphthyl, benzodioxolyl, heteroaryl, W-substituted heteroaryl, benzofused heteroaryl, W-substituted benzofused heteroaryl and cyclopropyl, wherein heteroaryl is as defined above;
(8) a sterol absorption inhibitor represented by Formula (VII):
(9) or a pharmaceutically acceptable salt or solvate thereof, wherein in Formula (VII):
A is -CH=CH-, -C.ident.C- or -(CH2)p- wherein p is 0, 1 or 2;
B is E is C10 to C20 alkyl or -C(O)-(C9 to C19)-alkyl, wherein the alkyl is straight or branched, saturated or containing one or more double bonds;
R is hydrogen, C1-C15 alkyl, straight or branched, saturated or containing one or more double bonds, or B-(CH2)r-, wherein r is 0, 1, 2, or 3;
R1, R2, and R3 are independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, carboxy, NO2, NH2, OH, halogeno, lower alkylamino, dilower alkylamino, -NHC(O)OR5, R6O2SNH- and -S(O)2NH2;
R4 is wherein n is 0, 1, 2 or 3;
R5 is lower alkyl; and R6 is OH, lower alkyl, phenyl, benzyl or substituted phenyl wherein the substituents are 1-3 groups independently selected from the group consisting of lower alkyl, lower alkoxy, carboxy, NO2, NH2, OH, halogeno, lower alkylamino and dilower alkylamino;
(10) a sterol absorption inhibitor represented by Formula (VIII):
(11) or a pharmaceutically acceptable salt or solvate thereof, wherein in Formula (VIII) above:
R26 is H or OG1;
G and G1 are independently selected from the group consisting of ; provided that when R26 is H or OH, G is not H;
R, R a and R b are independently selected from the group consisting of H, -OH, halogeno, -NH2, azido, (C1-C6)alkoxy(C1-C6)-alkoxy or -W-R30;
W is independently selected from the group consisting of -NH-C(O)-, -O-C(O)-, -O-C(O)-N(R31)-, -NH-C(O)-N(R31)- and -O-C(S)-N(R31)-;
R2 and R6 are independently selected from the group consisting of H, (C1-C6)alkyl, aryl and aryl(C1-C6)alkyl;
R3, R4, R5, R7, R3a and R4a are independently selected from the group consisting of H, (C1-C6)alkyl, aryl(C1-C6)alkyl, -C(O)(C1-C6)alkyl and -C(O) aryl;
R30 is selected from the group consisting of R32-substituted T, R32-substituted-T-(C1-C6)alkyl, R32-substituted-(C2-C4)alkenyl, R32-substituted-(C1-C6)alkyl, R32-substituted-(C3-C7)cycloalkyl and R32-substituted-(C3-C7)cycloalkyl(C1-C6)alkyl;
R31 is selected from the group consisting of H and (C1-C4)alkyl;
T is selected from the group consisting of phenyl, furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, iosthiazolyl, benzothiazolyl, thiadiazolyl, pyrazolyl, imidazolyl and pyridyl;
R32 is independently selected from 1-3 substituents independently selected from the group consisting of halogeno, (C1-C4)alkyl, -OH, phenoxy, -CF3, -NO2, (C1-C4)alkoxy, methylenedioxy, oxo, (C1-C4)alkylsulfanyl, (C1-C4)alkylsulfinyl, (C1-C4)alkylsulfonyl, -N(CH3)2, -C(O)-NH(C1-C4)alkyl, -C(O)-N((C1-C4)alkyl)2, -C(O)-(C1-C4)alkyl, -C(O)-(C1-C4)alkoxy and pyrrolidinylcarbonyl; or R32 is a covalent bond and R31, the nitrogen to which it is attached and R32 form a pyrrolidinyl, piperidinyl, N-methyl-piperazinyl, indolinyl or morpholinyl group, or a (C1-C4)alkoxycarbonyl-substituted pyrrolidinyl, piperidinyl, N-methylpiperazinyl, indolinyl or morpholinyl group;
Ar1 is aryl or R10-substituted aryl;
Ar2 is aryl or R11-substituted aryl;
Q is a bond or, with the 3-position ring carbon of the azetidinone, forms the spiro group ; and R1 is selected from the group consisting of -(CH2)q-, wherein q is 2-6, provided that when Q forms a spiro ring, q can also be zero or 1;
-(CH2)e-E-(CH2)r-, wherein E is -O-, -C(O)-, phenylene, -NR22- or -S(O)0-2-, e is 0-5 and r is 0-5, provided that the sum of e and r is 1-6;
-(C2-C6)alkenylene-; and -(CH2)-f-V-(CH2)g-, wherein V is C3-C6 cycloalkylene, f is 1-5 and g is 0-5, provided that the sum of f and g is 1-6;
R12 is R13 and R14 are independently selected from the group consisting of -CH2-, -CH(C1-C6 alkyl)-, -C(di-(C1-C6) alkyl), -CH=CH- and -C(C1-C6 alkyl)=CH-; or R12 together with an adjacent R13, or R12 together with an adjacent R14, form a -CH=CH- or a -CH=C(C1-C6 alkyl)- group;
a and b are independently 0, 1, 2 or 3, provided both are not zero;
provided that when R13 is -CH=CH- or -C(C1-C6 alkyl)=CH-, a is 1;
provided that when R14 is -CH=CH- or -C(C1-C6 alkyl)=CH-, b is 1;
provided that when a is 2 or 3, the R13's can be the same or different; and provided that when b is 2 or 3, the R14's can be the same or different;
and when Q is a bond, R1 also can be:
M is -O-, -S-, -S(O)- or -S(O)2-;
X, Y and Z are independently selected from the group consisting of -CH2-, -CH(C1-C6)alkyl- and -C(di-(C1-C6)alkyl);
R10 and R11 are independently selected from the group consisting of 1-3 substituents independently selected from the group consisting of (C1-C6)alkyl, -OR19, -O(CO)R19, -O(CO)OR21, -O(CH2)1-5OR19, -O(CO)NR19R20, -NR19R20, -NR19(CO)R20, -NR19(CO)OR21, -NR19(CO)NR20R25, -NR19SO2R21, -COOR19, -CONR19R20, -COR19, -SO2NR19R20, S(O)0-2R21, -O(CH2)1-10-COOR19, -O(CH2)1-10CONR19R20, -(C1-C6 alkylene)-COOR19, -CH=CH-COOR19, -CF3, -CN, -NO2 and halogen;
R15 and R17 are independently selected from the group consisting of -OR19, -O(CO)R19, -O(CO)OR21 and -O(CO)NR19R20;
R16 and R18 are independently selected from the group consisting of H, (C1-C6)alkyl and aryl; or R15 and R16 together are =O, or R17 and R18 together are =O;
d is 1, 2 or 3;
h is 0, 1, 2, 3 or 4;
s is 0 or 1; t is 0 or 1; m, n and p are independently 0-4;
provided that at least one of s and t is 1, and the sum of m, n, p, s and t is 6;
provided that when p is 0 and t is 1, the sum of m, s and n is 1-5; and provided that when p is 0 and s is 1, the sum of m, t and n is 1-5;
v is 0 or 1;
j and k are independently 1-5, provided that the sum of j, k and v is 1-5;
and when Q is a bond and R1 is , Ar1 can also be ~
pyridyl, isoxazolyl, furanyl, pyrrolyl, thienyl, imidazolyl, pyrazolyl, thiazolyl, pyrazinyl, pyrimidinyl or pyridazinyl;
R19 and R20 are independently selected from the group consisting of H, (C1-C6)alkyl, aryl and aryl-substituted (C1-C6)alkyl;
R21 is (C1-C6)alkyl, aryl or R24-substituted aryl;
R22 is H, (C1-C6)alkyl, aryl (C1-C6)alkyl, -C(O)R19 or -COOR19;
R23 and R24 are independently 1-3 groups independently selected from the group consisting of H, (C1-C6)alkyl, (C1-C6)alkoxy, -COOH, NO2, -NR19R20, -OH and halogeno; and R25 is H, -OH or (C1-C6)alkoxy; and (12) a sterol absorption inhibitor represented by Formula (IX):
(13) or a pharmaceutically acceptable salt or solvate thereof, wherein, in Formula (IX) above, R26 is selected from the group consisting of:
a) OH;
b) OCH3;
c) fluorine and d) chlorine;
R1 is selected from the group consisting of -SO3H; natural and unnatural amino acids;
R, R a and R b are independently selected from the group consisting of H, -OH, halogeno, -NH2, azido, (C1-C6)alkoxy(C1-C6)-alkoxy and -W-R30;
W is independently selected from the group consisting of -NH-C(O)-, -O-C(O)-, -O-C(O)-N(R31)-, -NH-C(O)-N(R31)- and -O-C(S)-N(R31)-;
R2 and R6 are independently selected from the group consisting of H, (C1-C6)alkyl, aryl and aryl(C1-C6)alkyl;
R3, R4, R5, R7, R3a and R4a are independently selected from the group consisting of H, (C1-C6)alkyl, aryl(C1-C6)alkyl, -C(O)(C1-C6)alkyl and -C(O)aryl;
R30 is independently selected form the group consisting of R32-substituted T, R32-substituted-T-(C1-C6)alkyl, R32-substituted-(C2-C4)alkenyl, R32-substituted-(C1-C6)alkyl, R32-substituted-(C3-C7)cycloalkyl and R32-substituted-(C3-C7)cycloalkyl(C1-C6)alkyl;
R31 is independently selected from the group consisting of H and (C1-C4)alkyl;
T is independently selected from the group consisting of phenyl, furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, iosthiazolyl, benzothiazolyl;
thiadiazolyl, pyrazolyl, imidazolyl and pyridyl;
R32 is independently selected from 1-3 substituents independently selected from the group consisting of H, halogeno, (C1-C4)alkyl, -OH, phenoxy, -CF3, -NO2, (C1-C4)alkoxy, methylenedioxy, oxo, (C1-C4)alkylsulfanyl, (C1-C4)alkylsulfinyl, (C1-C4)alkylsulfonyl, -N(CH3)2, -C(O)-NH(C1-C4)alkyl, -C(O)-N((C1-C4)alkyl)2, -C(O)-(C1-C4)alkyl, -C(O)-(C1-C4)alkoxy and pyrrolidinylcarbonyl; or R32 is a covalent bond and R31, the nitrogen to which it is attached and R32 form a pyrrolidinyl, piperidinyl, N-methyl-piperazinyl, indolinyl or morpholinyl group, or a (C1-C4)alkoxycarbonyl-substituted pyrrolidinyl, piperidinyl, N-methylpiperazinyl, indolinyl or morpholinyl group;
Ar1 is aryl, R10-substituted aryl; pyridyl, isoxazolyl, furanyl, pyrrolyl, thienyl, imidazolyl, pyrazolyl, thiazolyl, pyrazinyl, pyrimidinyl or pyridazinyl;
Ar2 is aryl or R11-substituted aryl;
Q is -(CH2)q-, wherein q is 2-6, or, with the 3-position ring carbon of the azetidinone, forms the spiro group ;
R12 is R13 and R14 are independently selected from the group consisting of -CH2-, -CH(C1-C6 alkyl)-, -C(di-(C1-C6) alkyl), -CH=CH- and -C(C1-C6 alkyl)=CH-;
or R12 together with an adjacent R13, or R12 together with an adjacent R14, form a -CH=CH- or a -CH=C(C1-C6 alkyl)- group;
a and b are independently 0, 1, 2 or 3, provided both are not zero; provided that when R13 is -CH=CH- or -C(C1-C6 alkyl)=CH-, a is 1; provided that when R14 is -CH=CH- or -C(C1-C6 alkyl)=CH-, b is 1; provided that when a is 2 or 3, the R13's can be the same or different; and provided that when b is 2 or 3, the R14's can be the same or different;
R10 and R11 are independently selected from the group consisting of 1-3 substituents independently selected from the group consisting of (C1-C6)alkyl, -OR19, -O(CO)R19, -O(CO)OR21, -O(CH2)1-5OR19, -O(CO)NR19R20, -NR19R20, -NR19(CO)R20, -NR19(CO)OR21, -NR19(CO)NR20R25, -NR19SO2R21, -COOR19, -CONR19R20, -COR19, -SO2NR19R20, -S(O)0-2R21, -O(CH2)1-10-COOR19, -O(CH2)1-10CONR19R20, -(C1-C6 alkylene)-COOR19, -CH=CH-COOR19, -CF3, -CN, -NO2 and halogen;
R19 and R20 are independently selected from the group consisting of H, (C1-C6)alkyl, aryl and aryl-substituted (C1-C6)alkyl;
R21 is (C1-C6)alkyl, aryl or R24-substituted aryl;
R22 is H, (C1-C6)alkyl, aryl (C1-C6)alkyl, -C(O)R19 or -COOR19;
R23 and R24 are independently 1-3 groups independently selected from the group consisting of H, (C1-C6)alkyl, (C1-C6)alkoxy, -COOH, NO2, -NR19R20, -OH and halogeno; and R25 is H, -OH or (C1-C6)alkoxy;
(b) lactose monohydrate;
(c) microcrystalline cellulose;
(d) povidone;
(e) croscarmellose sodium;
(f) sodium lauryl sulfate; and (g) magnesium stearate.
69. The composition according to claim 68, wherein the sterol absorption inhibitor is represented by Formula (X):
or a pharmaceutically acceptable salt or solvate of the compound of Formula (X), wherein R1 is defined as in Formula (IX) in claim 68.
or a pharmaceutically acceptable salt or solvate of the compound of Formula (X), wherein R1 is defined as in Formula (IX) in claim 68.
70. The composition according to claim 68, wherein the sterol absorption inhibitor is represented by Formula (XI):
or a pharmaceutically acceptable salt or solvate of the compound of Formula (XI).
or a pharmaceutically acceptable salt or solvate of the compound of Formula (XI).
71. A composition of any one of claims 68 to 70 for use in the treatment or prevention of a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal.
72. Use of a composition of any one of claims 68 to 70 in the manufacture of a medicament for treating or preventing a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal.
73. A therapeutic combination comprising:
(a) a first amount of the composition of any one of claims 68 to 70; and (b) at least one cholesterol biosynthesis inhibitor, wherein the first amount and the second amount together comprise a therapeutically effective amount for the treatment or prevention of a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal.
(a) a first amount of the composition of any one of claims 68 to 70; and (b) at least one cholesterol biosynthesis inhibitor, wherein the first amount and the second amount together comprise a therapeutically effective amount for the treatment or prevention of a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal.
74. Use of the composition of any one of claims 68 to 70, in the manufacture of a medicament for treating or preventing a vascular condition, obesity, diabetes or lowering a concentration of a sterol in plasma of a mammal.
75. Use of a composition of any one of claims 1 to 33, for preparation of a medicament for treating or preventing a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal.
76. Use of a therapeutic combination of any one of claims 34 to 63, for preparation of a medicament for treating or preventing a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26439601P | 2001-01-26 | 2001-01-26 | |
US60/264,396 | 2001-01-26 | ||
US32383901P | 2001-09-21 | 2001-09-21 | |
US60/323,839 | 2001-09-21 | ||
CA002434682A CA2434682C (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002434682A Division CA2434682C (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2562982A1 true CA2562982A1 (en) | 2002-08-01 |
CA2562982C CA2562982C (en) | 2011-03-15 |
Family
ID=26950511
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2562982A Expired - Fee Related CA2562982C (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
CA002563051A Abandoned CA2563051A1 (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
CA002434682A Expired - Lifetime CA2434682C (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002563051A Abandoned CA2563051A1 (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
CA002434682A Expired - Lifetime CA2434682C (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
Country Status (33)
Country | Link |
---|---|
US (5) | US20020151536A1 (en) |
EP (2) | EP1413331B1 (en) |
JP (4) | JP4777602B2 (en) |
KR (1) | KR100596257B1 (en) |
CN (1) | CN100509058C (en) |
AR (2) | AR033855A1 (en) |
AT (2) | ATE374641T1 (en) |
AU (1) | AU2002247019C1 (en) |
BR (1) | BR0206654A (en) |
CA (3) | CA2562982C (en) |
CL (1) | CL2004001174A1 (en) |
CY (2) | CY1108000T1 (en) |
CZ (2) | CZ301871B6 (en) |
DE (2) | DE60222773T2 (en) |
DK (2) | DK1413331T3 (en) |
EC (1) | ECSP11004702A (en) |
ES (2) | ES2290562T3 (en) |
HK (2) | HK1063607A1 (en) |
HU (2) | HU230253B1 (en) |
IL (3) | IL156445A0 (en) |
ME (1) | MEP27808A (en) |
MX (1) | MXPA03006725A (en) |
NO (1) | NO331512B1 (en) |
NZ (1) | NZ525921A (en) |
PL (1) | PL208110B1 (en) |
PT (2) | PT1413331E (en) |
RS (2) | RS51449B (en) |
RU (1) | RU2356550C2 (en) |
SI (2) | SI1413331T1 (en) |
SK (2) | SK288217B6 (en) |
TW (1) | TWI337083B (en) |
WO (1) | WO2002058732A2 (en) |
ZA (1) | ZA200305693B (en) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1363668T1 (en) * | 2001-01-26 | 2007-12-31 | Schering Corp | Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
EP1671650A1 (en) * | 2001-01-26 | 2006-06-21 | Schering Corporation | Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications |
ATE345793T1 (en) * | 2001-09-21 | 2006-12-15 | Schering Corp | TREATMENT OF XANTHOMA USING AZETIDINONE DERIVATIVES AS STEROL ABSORPTION INHIBITORS |
EP1465667A4 (en) | 2001-09-24 | 2007-06-27 | Merck & Co Inc | Screening and selection methods for statin drug combinations |
GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
US7135556B2 (en) * | 2002-07-19 | 2006-11-14 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
AR040588A1 (en) | 2002-07-26 | 2005-04-13 | Schering Corp | PHARMACEUTICAL FORMULATION INCLUDING AN INHIBITOR OF CHOLESTEROL ABSORPTION AND AN INHIBITOR OF A HMGCO TO REDUCTASE |
BR0314710A (en) * | 2002-09-27 | 2005-07-26 | Martek Biosciences Corp | Prophylactic Decosahexenoic Acid Therapy for Patients with Subclinical Inflammation |
ES2544560T3 (en) * | 2002-12-16 | 2015-09-01 | Kissei Pharmaceutical Co., Ltd. | Solid drug for oral use |
WO2004069193A2 (en) * | 2003-02-03 | 2004-08-19 | Thomas Jefferson University | Methods and compositions for inhibiting cholesterol uptake |
ATE418551T1 (en) | 2003-03-07 | 2009-01-15 | Schering Corp | SUBSTITUTED AZETIDINONE DERIVATIVES, THEIR PHARMACEUTICAL FORMULATIONS AND THEIR USE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA |
US7235543B2 (en) | 2003-03-07 | 2007-06-26 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
JP2005015434A (en) * | 2003-06-27 | 2005-01-20 | Kotobuki Seiyaku Kk | Serum cholesterol-lowering agent or prophylactic or therapeutic agent for atherosclerosis |
JP2007510659A (en) * | 2003-11-05 | 2007-04-26 | シェーリング コーポレイション | Combinations of lipid modulators and substituted azetidinones and treatment of vascular conditions |
JP4839221B2 (en) * | 2003-11-07 | 2011-12-21 | ジェイ ジェイ ファーマ,インコーポレイテッド | Combination therapy combination to increase HDL |
SA04250427A (en) | 2003-12-23 | 2005-12-03 | استرازينيكا ايه بي | Diphenylazetidone derivates |
WO2005069900A2 (en) * | 2004-01-16 | 2005-08-04 | Merck & Co., Inc. | Npc1l1 (npc3) and methods of identifying ligands thereof |
US20070116645A1 (en) * | 2004-02-03 | 2007-05-24 | Steven Farber | Methods and compositions for inhibiting cholesterol uptake |
US7838552B2 (en) | 2004-06-04 | 2010-11-23 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
PL1750862T3 (en) | 2004-06-04 | 2011-06-30 | Teva Pharma | Pharmaceutical composition containing irbesartan |
US7803838B2 (en) * | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
CN1759834B (en) * | 2004-09-17 | 2010-06-23 | 中国医学科学院医药生物技术研究所 | Application of berberine or associated with Simvastatin in preparing product for preventing or curing disease or symptom related to blood fat |
US7524831B2 (en) * | 2005-03-02 | 2009-04-28 | Schering Corporation | Treatments for Flaviviridae virus infection |
UY29607A1 (en) | 2005-06-20 | 2007-01-31 | Astrazeneca Ab | CHEMICAL COMPOUNDS |
AR057072A1 (en) | 2005-06-22 | 2007-11-14 | Astrazeneca Ab | CHEMICAL COMPOUNDS DERIVED FROM 2-AZETIDINONE, PHARMACEUTICAL FORMULATION AND A COMPOUND PREPARATION PROCESS |
SA06270191B1 (en) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | Novel 2-Azetidinone Derivatives as Cholesterol Absorption Inhibitors for the Treatment of Hyperlipidaemic Conditions |
EP1741427A1 (en) * | 2005-07-06 | 2007-01-10 | KRKA, D.D., Novo Mesto | Pharmaceutical composition comprising simvastatin and ezetimibe |
EA200800356A1 (en) * | 2005-07-18 | 2008-10-30 | Релайэнт Фармасьютикалз, Инк. | TREATING CHOLESTEROL ABSORPTION WITH AZETIDINONE AND OMEGA-3 INHIBITOR WITH FATTY ACIDS AND THEIR COMBINED DRUG |
US7910698B2 (en) * | 2006-02-24 | 2011-03-22 | Schering Corporation | NPC1L1 orthologues |
TW200811098A (en) | 2006-04-27 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
US20070275052A1 (en) * | 2006-05-24 | 2007-11-29 | Glenmark Pharmaceuticals Limited | Pharmaceutical compositions containing sterol inhibitors |
US20070299017A1 (en) * | 2006-06-23 | 2007-12-27 | Kanter Mitchell M | Compositions for lowering blood serum cholesterol and use in foods, beverages, and health supplements |
US20080033019A1 (en) * | 2006-08-07 | 2008-02-07 | Duke University | Cholesterol lowering drug combination |
US20080085315A1 (en) * | 2006-10-10 | 2008-04-10 | John Alfred Doney | Amorphous ezetimibe and the production thereof |
ATE530178T1 (en) * | 2007-05-23 | 2011-11-15 | Amcol International Corp | PHYLLOSSILICATES INTERACTING WITH CHOLESTEROL AND METHOD FOR REDUCING HYPERCHOLESTEROLEMIA IN A MAMMAL |
ES2639995T3 (en) | 2007-12-10 | 2017-10-31 | Ratiopharm Gmbh | Pharmaceutical formulation comprising ezetimibe |
EP2168573A1 (en) | 2008-09-30 | 2010-03-31 | LEK Pharmaceuticals D.D. | Formulations comprising ezetimibe |
WO2010085811A2 (en) * | 2009-01-26 | 2010-07-29 | Taipei Medical University | Use of pterosin compounds for treating diabetes and obesity |
ATE536172T1 (en) | 2009-03-13 | 2011-12-15 | Sanovel Ilac Sanayi Ve Ticaret As | EZETIMIBE COMPOSITIONS |
CA2757722C (en) | 2009-04-01 | 2018-05-22 | Matrix Laboratories Ltd. | Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe |
TR200904500A2 (en) | 2009-06-10 | 2009-10-21 | Öner Levent | Methods and pharmaceutical formulations for the preparation of ezetimibe nanocrystals. |
TWI598098B (en) | 2012-09-27 | 2017-09-11 | 興和股份有限公司 | Therapeutic agent for dyslipidemia |
KR20150079373A (en) | 2013-12-30 | 2015-07-08 | 한미약품 주식회사 | Composite formulation for oral administration comprising ezetimibe and rosuvastatin |
CN104337785A (en) * | 2014-11-04 | 2015-02-11 | 万全万特制药江苏有限公司 | Orally disintegrating tablet containing ezetimibe and preparation method of orally disintegrating tablet |
CN105213340A (en) * | 2015-10-29 | 2016-01-06 | 无锡福祈制药有限公司 | A kind of Ezetimibe sheet and preparation method thereof |
JP2017210455A (en) * | 2016-05-27 | 2017-11-30 | ニプロ株式会社 | Ezetimibe-containing pharmaceutical composition |
CN106310173A (en) * | 2016-08-24 | 2017-01-11 | 厦门三川利生物科技有限公司 | Multi-vitamin acidity alcohol containing peroxisome proliferator activated receptor and preparing method thereof |
EP3437636A1 (en) | 2017-08-02 | 2019-02-06 | Adamed sp. z o.o. | Pharmaceutical composition comprising ezetimibe |
CN109718215A (en) * | 2017-10-30 | 2019-05-07 | 海南皇隆制药股份有限公司 | A kind of Ezetimibe piece |
KR101983298B1 (en) * | 2018-06-11 | 2019-05-29 | 연세대학교 산학협력단 | Pharmaceutical coomposition for preventing or treating inflammasome mediated inflammatory disease |
Family Cites Families (174)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2809194A (en) * | 1957-10-08 | Thiadiazine type natriuretic agents | ||
US3108097A (en) * | 1963-10-22 | Ehnojs | ||
US1286A (en) * | 1839-08-13 | Richard else | ||
BE578515A (en) * | 1958-05-07 | |||
NL127065C (en) * | 1964-04-22 | |||
NL137318C (en) * | 1964-06-09 | |||
US3716583A (en) * | 1969-04-16 | 1973-02-13 | Sumitomo Chemical Co | Phenoxy carboxylic acid derivative |
US3692895A (en) * | 1970-09-08 | 1972-09-19 | Norman A Nelson | Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria |
DE2230383C3 (en) * | 1971-10-01 | 1981-12-03 | Boehringer Mannheim Gmbh, 6800 Mannheim | Phenoxyalkylcarboxylic acid derivatives and processes for making the same |
US4148923A (en) * | 1972-05-31 | 1979-04-10 | Synthelabo | 1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity |
US3948973A (en) * | 1972-08-29 | 1976-04-06 | Sterling Drug Inc. | Halocyclopropyl substituted phenoxyalkanoic acids |
US4626549A (en) * | 1974-01-10 | 1986-12-02 | Eli Lilly And Company | Treatment of obesity with aryloxyphenylpropylamines |
US4179515A (en) * | 1975-02-12 | 1979-12-18 | Orchimed S. A. | Benzoylphenoxy propionic acid, esters thereof and pharmaceutical composition |
US4235896A (en) * | 1975-02-12 | 1980-11-25 | Orchimed S.A. | Benzyl-phenoxy acid esters and hyperlipaemia compositions containing the same |
JPS5195049A (en) * | 1975-02-12 | 1976-08-20 | * **********so*****no***tsu*****************************************ni*no | |
US4075000A (en) * | 1975-05-27 | 1978-02-21 | Eli Lilly And Company | Herbicidal use of 4-amino-3,3-dimethyl-1-phenyl-2-azetidinones |
US4472309A (en) * | 1975-10-06 | 1984-09-18 | Fujisawa Pharmaceutical Co., Ltd. | 2-Azetidinone compounds and processes for preparation thereof |
US4304718A (en) * | 1975-10-06 | 1981-12-08 | Fujisawa Pharmaceutical Co., Ltd. | 2-Azetidinone compounds and processes for preparation thereof |
US4576753A (en) * | 1975-10-06 | 1986-03-18 | Fujisawa Pharmaceutical Co., Ltd. | Azetidinone compounds and processes for preparation thereof |
US4166907A (en) * | 1976-11-01 | 1979-09-04 | E. R. Squibb & Sons, Inc. | 3,3-Dichloro-2-azetidinone derivatives having antiinflammatory activity |
US4144232A (en) * | 1976-12-23 | 1979-03-13 | Eli Lilly And Company | Substituted azetidin-2-one antibiotics |
FR2403078A1 (en) * | 1977-09-19 | 1979-04-13 | Lafon Labor | NEW PROCESS FOR THE PREPARATION OF PHARMACEUTICAL, COSMETIC OR DIAGNOSIS FORMS |
IT1157365B (en) * | 1977-10-24 | 1987-02-11 | Sandoz Ag | MEDICATIONS TO TREAT OBESITY OR REDUCE BODY WEIGHT |
US4250191A (en) * | 1978-11-30 | 1981-02-10 | Edwards K David | Preventing renal failure |
US4375475A (en) * | 1979-08-17 | 1983-03-01 | Merck & Co., Inc. | Substituted pyranone inhibitors of cholesterol synthesis |
US4260743A (en) * | 1979-12-31 | 1981-04-07 | Gist-Brocades N.V. | Preparation of β-lactams and intermediates therefor |
US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
DE3107100A1 (en) * | 1981-02-20 | 1982-09-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | AZAPROSTACYCLINE, METHOD FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE |
US4500456A (en) * | 1981-03-09 | 1985-02-19 | Eli Lilly And Company | Preparation of 4-fluoroazetidinones using FClO3 |
US4784734A (en) * | 1981-04-10 | 1988-11-15 | Otsuka Kagaku Yakuhin Kabushiki Kaisha | Azetidinone derivatives and process for the preparation of the same |
US4602003A (en) * | 1982-05-17 | 1986-07-22 | Medical Research Foundation Of Oregon | Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia |
US4602005A (en) * | 1982-05-17 | 1986-07-22 | Medical Research Foundation Of Oregon | Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis |
US4443372A (en) * | 1982-06-23 | 1984-04-17 | Chevron Research Company | 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators |
US4534786A (en) * | 1982-06-23 | 1985-08-13 | Chevron Research Company | 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators |
US4595532A (en) * | 1983-02-02 | 1986-06-17 | University Of Notre Dame Du Lac | N-(substituted-methyl)-azetidin-2-ones |
CA1256650A (en) * | 1983-03-25 | 1989-06-27 | Toshinari Tamura | Process of producing 2-azetidinone-4-substituted compounds, and medicaments containing the compounds |
US4675399A (en) * | 1983-03-28 | 1987-06-23 | Notre Dame University | Cyclization process for β-lactams |
EP0126709B1 (en) * | 1983-03-28 | 1991-04-03 | Ciba-Geigy Ag | Process for the preparation of optically active azetidinones |
WO1985004876A1 (en) * | 1984-04-24 | 1985-11-07 | Takeda Chemical Industries, Ltd. | 2-azetidinone derivatives and process for their preparation |
US4576749A (en) * | 1983-10-03 | 1986-03-18 | E. R. Squibb & Sons, Inc. | 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones |
US4680391A (en) * | 1983-12-01 | 1987-07-14 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
US5229381A (en) * | 1983-12-01 | 1993-07-20 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
US5229510A (en) * | 1983-12-01 | 1993-07-20 | Merck & Co., Inc. | β-lactams useful in determining the amount of elastase in a clinical sample |
US4654362A (en) * | 1983-12-05 | 1987-03-31 | Janssen Pharmaceutica, N.V. | Derivatives of 2,2'-iminobisethanol |
FR2561916B1 (en) * | 1984-03-30 | 1987-12-11 | Lafon Labor | GALENIC FORM FOR ORAL ADMINISTRATION AND METHOD FOR PREPARING IT BY LYOPHILIZATION OF AN OIL-TO-WATER EMISSION |
US4633017A (en) * | 1984-08-03 | 1986-12-30 | E. R. Squibb & Sons, Inc. | N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones |
US4581170A (en) * | 1984-08-03 | 1986-04-08 | E. R. Squibb & Sons, Inc. | N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones |
US4576748A (en) * | 1984-09-17 | 1986-03-18 | Merck & Co., Inc. | 3-Hydroxy-3-aminoethyl β-lactams |
US4620867A (en) * | 1984-09-28 | 1986-11-04 | Chevron Research Company | 1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides |
AR240698A1 (en) * | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Process for the preparation of 5-(4-(2-(5-ethyl-2-pyridil)-ethoxy)benzyl)-2,4-thiazolodinedione and their salts |
US4642903A (en) * | 1985-03-26 | 1987-02-17 | R. P. Scherer Corporation | Freeze-dried foam dosage form |
US4680289A (en) * | 1985-06-05 | 1987-07-14 | Progenics, Inc. | Treatment of obesity and diabetes using sapogenins |
DE3787815T2 (en) * | 1986-02-19 | 1994-03-24 | Sanraku Inc | Azetidinone derivatives. |
GB8607312D0 (en) * | 1986-03-25 | 1986-04-30 | Ici Plc | Therapeutic agents |
FR2598146B1 (en) * | 1986-04-30 | 1989-01-20 | Rech Ind | NEW PROCESS FOR THE PREPARATION OF FIBRATES. |
DE3621861A1 (en) * | 1986-06-30 | 1988-01-14 | Laszlo Dr Med Ilg | USE OF ARYLOXYCARBONIC ACID DERIVATIVES AGAINST DERMATOLOGICAL DISEASES |
FR2602423B1 (en) * | 1986-08-08 | 1989-05-05 | Ethypharm Sa | PROCESS FOR THE PREPARATION OF A FENOFIBRATE-BASED MEDICINAL PRODUCT, OBTAINED BY THIS PROCESS |
US4814354A (en) * | 1986-09-26 | 1989-03-21 | Warner-Lambert Company | Lipid regulating agents |
US4803266A (en) * | 1986-10-17 | 1989-02-07 | Taisho Pharmaceutical Co., Ltd. | 3-Oxoalkylidene-2-azetidinone derivatives |
PH25145A (en) * | 1986-12-15 | 1991-02-19 | Laverne Dwaine Boeck | Process for producing the a10255 complex and corresponding microorganism |
US5229362A (en) * | 1986-12-15 | 1993-07-20 | Eli Lilly And Company | Antibiotic A10255 complex and factors, and process and production therefor |
JPS63156788A (en) * | 1986-12-22 | 1988-06-29 | Sanraku Inc | Optically active azetidinones |
US5110730A (en) * | 1987-03-31 | 1992-05-05 | The Scripps Research Institute | Human tissue factor related DNA segments |
EP0288973B1 (en) * | 1987-04-28 | 1993-01-13 | Fujisawa Astra Ltd. | Benzothiazolinone derivatives, their production and pharmaceutical composition |
US5106833A (en) * | 1987-07-23 | 1992-04-21 | Washington University | Coagulation inhibitors |
US5091525A (en) * | 1987-10-07 | 1992-02-25 | Eli Lilly And Company | Monohydrate and DMF solvates of a new carbacephem antibiotic |
US4834846A (en) * | 1987-12-07 | 1989-05-30 | Merck & Co., Inc. | Process for deblocking N-substituted β-lactams |
US5385885A (en) * | 1988-01-15 | 1995-01-31 | Gasic; Gregory P. | Inhibition of smooth muscle cell proliferation by antistasin and tick anticoagulant peptide |
FR2627696B1 (en) * | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | NEW GALENIC FORM OF FENOFIBRATE |
DE3807895A1 (en) * | 1988-03-10 | 1989-09-21 | Knoll Ag | PRODUCTS CONTAINING A CALCIUM ANTAGONIST AND A LIPID DOWNER |
GB8813012D0 (en) * | 1988-06-02 | 1988-07-06 | Norsk Hydro As | Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals |
FR2634376B1 (en) * | 1988-07-21 | 1992-04-17 | Farmalyoc | NOVEL SOLID AND POROUS UNIT FORM COMPRISING MICROPARTICLES AND / OR NANOPARTICLES, AS WELL AS ITS PREPARATION |
US4952689A (en) * | 1988-10-20 | 1990-08-28 | Taisho Pharmaceutical Co., Ltd. | 3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation |
CA1340977C (en) * | 1988-11-15 | 2000-04-25 | Monty Krieger | Scavenger receptor protein and antibody thereto |
US5073374A (en) * | 1988-11-30 | 1991-12-17 | Schering Corporation | Fast dissolving buccal tablet |
US5112616A (en) * | 1988-11-30 | 1992-05-12 | Schering Corporation | Fast dissolving buccal tablet |
US4876365A (en) * | 1988-12-05 | 1989-10-24 | Schering Corporation | Intermediate compounds for preparing penems and carbapenems |
US5260305A (en) * | 1988-12-12 | 1993-11-09 | E. R. Squibb & Sons, Inc. | Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination |
FR2640621B1 (en) * | 1988-12-19 | 1992-10-30 | Centre Nat Rech Scient | N-ARYL-AZETIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ELASTASE INHIBITORS |
US4990535A (en) * | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
CA2016467A1 (en) | 1989-06-05 | 1990-12-05 | Martin Eisman | Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor |
JPH03108490A (en) * | 1989-06-30 | 1991-05-08 | Shionogi & Co Ltd | Phospholipase a2 inhibitor |
US5021461A (en) * | 1989-07-26 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Method of treating diabetes mellitus with bisphenol derivatives |
US4983597A (en) * | 1989-08-31 | 1991-01-08 | Merck & Co., Inc. | Beta-lactams as anticholesterolemic agents |
US5219574A (en) * | 1989-09-15 | 1993-06-15 | Cima Labs. Inc. | Magnesium carbonate and oil tableting aid and flavoring additive |
US5178878A (en) * | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
US5223264A (en) * | 1989-10-02 | 1993-06-29 | Cima Labs, Inc. | Pediatric effervescent dosage form |
US5188825A (en) * | 1989-12-28 | 1993-02-23 | Iles Martin C | Freeze-dried dosage forms and methods for preparing the same |
US5298497A (en) * | 1990-05-15 | 1994-03-29 | E. R. Squibb & Sons, Inc. | Method for preventing onset of hypertension employing a cholesterol lowering drug |
US5622985A (en) * | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
US5120729A (en) * | 1990-06-20 | 1992-06-09 | Merck & Co., Inc. | Beta-lactams as antihypercholesterolemics |
US5120713A (en) * | 1990-09-10 | 1992-06-09 | Applied Research Systems Ars Holding N.V. | Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide |
US5130333A (en) * | 1990-10-19 | 1992-07-14 | E. R. Squibb & Sons, Inc. | Method for treating type II diabetes employing a cholesterol lowering drug |
US5190970A (en) * | 1990-10-19 | 1993-03-02 | E. R. Squibb & Sons, Inc. | Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
JP2640986B2 (en) * | 1990-11-08 | 1997-08-13 | 高砂香料工業株式会社 | Process for producing (1'R, 3S) -3- (1'-hydroxyethyl) -azetidin-2-one or a derivative thereof |
IL100091A (en) * | 1990-12-12 | 1998-08-16 | Zeneca Ltd | Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
AU642066B2 (en) | 1991-01-25 | 1993-10-07 | Nanosystems L.L.C. | X-ray contrast compositions useful in medical imaging |
US5157025A (en) * | 1991-04-01 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug |
ATE158789T1 (en) | 1991-07-23 | 1997-10-15 | Schering Corp | SUBSTITUTED BETA-LACTAM COMPOUNDS AS HYPOCHOLESTEROLEMIC AGENTS AND METHOD FOR THE PRODUCTION THEREOF |
US5162117A (en) * | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
US5278176A (en) * | 1992-08-21 | 1994-01-11 | Abbott Laboratories | Nicotine derivatives that enhance cognitive function |
AU660852B2 (en) * | 1992-11-25 | 1995-07-06 | Elan Pharma International Limited | Method of grinding pharmaceutical substances |
US5503846A (en) * | 1993-03-17 | 1996-04-02 | Cima Labs, Inc. | Base coated acid particles and effervescent formulation incorporating same |
US5412092A (en) * | 1993-04-23 | 1995-05-02 | Bristol-Myers Squibb Company | N-substituted 2-azetidinones |
KR0176001B1 (en) * | 1993-07-09 | 1999-03-20 | 에릭 에스. 딕커 | Process for the synthesis of azetidinones |
EP0804170B1 (en) * | 1993-07-09 | 2001-11-14 | R.P. Scherer Corporation | Method for making freeze dried drug dosage forms |
US5622719A (en) * | 1993-09-10 | 1997-04-22 | Fuisz Technologies Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5595761A (en) * | 1994-01-27 | 1997-01-21 | The Board Of Regents Of The University Of Oklahoma | Particulate support matrix for making a rapidly dissolving tablet |
US5627176A (en) * | 1994-03-25 | 1997-05-06 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
TW384224B (en) * | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
US5718388A (en) * | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
WO1995035277A1 (en) * | 1994-06-20 | 1995-12-28 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
US5624920A (en) * | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5633246A (en) * | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
FR2730231B1 (en) * | 1995-02-02 | 1997-04-04 | Fournier Sca Lab | COMBINATION OF FENOFIBRATE AND VITAMIN E, USE IN THERAPEUTICS |
US5639475A (en) * | 1995-02-03 | 1997-06-17 | Eurand America, Incorporated | Effervescent microcapsules |
US5518738A (en) * | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
US5591456A (en) * | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
JP3144624B2 (en) * | 1995-06-02 | 2001-03-12 | 杏林製薬株式会社 | N-benzyldioxothiazolidylbenzamide derivative and method for producing the same |
US5612378A (en) * | 1995-06-06 | 1997-03-18 | 3-Dimensional Pharmaceuticals, Inc. | Bis-arylsulfonylaminobenzamide derivatives and the use thereof as factor Xa inhibitors |
US5607697A (en) * | 1995-06-07 | 1997-03-04 | Cima Labs, Incorporated | Taste masking microparticles for oral dosage forms |
US5612353A (en) * | 1995-06-07 | 1997-03-18 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds |
FR2738817B1 (en) * | 1995-09-14 | 1997-10-17 | Adir | NOVEL SUBSTITUTED ALKANOIC 2,2-DIMETHYL-OMEGA-PHENOXY ACIDS AND ESTERS, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US5618707A (en) * | 1996-01-04 | 1997-04-08 | Schering Corporation | Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof |
WO1997016424A1 (en) * | 1995-11-02 | 1997-05-09 | Schering Corporation | Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone |
GB9600464D0 (en) * | 1996-01-09 | 1996-03-13 | Smithkline Beecham Plc | Novel method |
US5859051A (en) * | 1996-02-02 | 1999-01-12 | Merck & Co., Inc. | Antidiabetic agents |
GB9606805D0 (en) * | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
EP0904082A4 (en) * | 1996-04-17 | 2001-09-26 | Merck & Co Inc | Combination therapy for reducing the risks associated with cardiovascular disease |
US5858409A (en) * | 1996-04-17 | 1999-01-12 | Fmc Corporation | Hydrolyzed cellulose granulations for pharmaceuticals |
CO4840511A1 (en) * | 1996-05-24 | 1999-09-27 | Schering Corp | ANTIFUNGAL COMPOSITION CONTAINING (2R-CIS) -4- [4- [4- [4- [[-5- (2,4-DIFLUOROPHENYL) TETRAHYDRO-5- (1H-1,2,4-TRIAZOL-1- ILMETIL) FURAN-3-IL] METOXI] FENIL] -1-PIPERAZINIL] FENIL] 2-4- DIHIDRO-2 - [(S) -1-ETIL-2 (S) -HIDROXIPROPIL-3H-1,2,4 - TRIAZOL-3-ONA |
US5886171A (en) * | 1996-05-31 | 1999-03-23 | Schering Corporation | 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones |
US5739321A (en) * | 1996-05-31 | 1998-04-14 | Schering Corporation | 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones |
KR19990036207A (en) * | 1996-06-12 | 1999-05-25 | 히라타 다다시 | Lipid metabolism improver |
US5883109A (en) * | 1996-07-24 | 1999-03-16 | Bristol-Myers Squibb Company | Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug |
FR2761266B1 (en) * | 1997-03-28 | 1999-07-02 | Sanofi Sa | PHARMACEUTICAL COMPOSITION FORMED BY WET GRANULATION FOR THE ORAL ADMINISTRATION OF A DERIVATIVE OF N-PIPERIDINO-3- PYRAZOLECARBOXAMIDE, ITS SALTS AND THEIR SOLVATES |
ATE530180T1 (en) * | 1997-04-02 | 2011-11-15 | Brigham & Womens Hospital | METHOD FOR DETERMINING THE INDIVIDUAL RISK PROFILES OF ATHEROSCLEROTIC DISEASES |
ES2125198B1 (en) * | 1997-05-13 | 1999-11-16 | Vita Invest Sa | FIXED-DOSE ASSOCIATION OF AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR AND AN ANTAGONIST OF THE CALCIUM CHANNELS, PROCEDURE FOR ITS PREPARATION AND USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES. |
US5886191A (en) * | 1997-08-18 | 1999-03-23 | Dupont Pharmaceuticals Company | Amidinoindoles, amidinoazoles, and analogs thereof |
US5869098A (en) * | 1997-08-20 | 1999-02-09 | Fuisz Technologies Ltd. | Fast-dissolving comestible units formed under high-speed/high-pressure conditions |
AR016827A1 (en) * | 1997-08-22 | 2001-08-01 | Smithkline Beecham Corp | PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL TABLET |
US6180660B1 (en) * | 1997-08-26 | 2001-01-30 | Merck & Co., Inc. | Cholesterol-lowering therapy |
US6207697B1 (en) * | 1997-09-09 | 2001-03-27 | Dupont Pharmaceuticals Company | Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor Xa |
US20030153541A1 (en) * | 1997-10-31 | 2003-08-14 | Robert Dudley | Novel anticholesterol compositions and method for using same |
US6027747A (en) * | 1997-11-11 | 2000-02-22 | Terracol; Didier | Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions |
US6008237A (en) * | 1997-12-19 | 1999-12-28 | Merck & Co., Inc. | Arylthiazolidinedione derivatives |
US6180625B1 (en) * | 1998-03-24 | 2001-01-30 | Novo Nordisk A/S | Heterocyclic compounds regulating clotting |
WO1999050255A2 (en) * | 1998-03-27 | 1999-10-07 | Du Pont Pharmaceuticals Company | Disubstituted pyrazolines and triazolines as factor xa inhibitors |
EP1073643B1 (en) * | 1998-04-23 | 2004-12-29 | Dr. Reddy's Laboratories Ltd. | New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
US6207822B1 (en) * | 1998-12-07 | 2001-03-27 | Schering Corporation | Process for the synthesis of azetidinones |
WO2000038725A1 (en) * | 1998-12-23 | 2000-07-06 | G.D. Searle Llc | Combinations for cardiovascular indications |
US6180138B1 (en) * | 1999-01-29 | 2001-01-30 | Abbott Laboratories | Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption |
US6033656A (en) * | 1999-05-04 | 2000-03-07 | Sumitomo Chemical Company, Limited | Method of preventing or alleviating mammalian obesity |
US6207699B1 (en) * | 1999-06-18 | 2001-03-27 | Richard Brian Rothman | Pharmaceutical combinations for treating obesity and food craving |
US6174665B1 (en) * | 1999-09-10 | 2001-01-16 | Biex, Inc. | Hormone replacement therapy monitoring |
PT1175220E (en) * | 1999-12-08 | 2005-07-29 | Pharmacia Corp | EPLERENONE COMPOSITIONS IN NANOPARTICLES |
US6191117B1 (en) * | 2000-07-10 | 2001-02-20 | Walter E. Kozachuk | Methods of producing weight loss and treatment of obesity |
US20020132855A1 (en) * | 2000-08-03 | 2002-09-19 | Nelson Edward B. | Use of acetaminophen to prevent and treat arteriosclerosis |
DE10042447A1 (en) * | 2000-08-29 | 2002-03-28 | Aventis Pharma Gmbh | Vertebrate intestinal protein that absorbs cholesterol and use of this protein to identify inhibitors of intestinal cholesterol transport |
JP2004513090A (en) * | 2000-09-27 | 2004-04-30 | メルク エンド カムパニー インコーポレーテッド | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and dyslipidemia |
WO2002050027A1 (en) * | 2000-12-21 | 2002-06-27 | Aventis Pharma Deutschland Gmbh | Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism |
EP1345924B1 (en) * | 2000-12-21 | 2006-08-30 | Sanofi-Aventis Deutschland GmbH | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
IL156552A0 (en) * | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
CA2434436A1 (en) * | 2001-01-26 | 2002-08-01 | Teddy Kosoglou | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
SI1363668T1 (en) * | 2001-01-26 | 2007-12-31 | Schering Corp | Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
WO2002064094A2 (en) * | 2001-02-09 | 2002-08-22 | Merck & Co., Inc. | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders |
EP1389114A2 (en) * | 2001-03-08 | 2004-02-18 | Merck & Co., Inc. | Antihypertensive agent and cholesterol absorption inhibitor combination therapy |
US7348334B2 (en) * | 2001-04-09 | 2008-03-25 | Dr. Reddy's Laboratories Limited | Monocyclic derivatives of aryl alkanoic acids and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
WO2002081454A1 (en) * | 2001-04-09 | 2002-10-17 | Dr. Reddy's Laboratories Ltd. | Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them |
CA2447884A1 (en) * | 2001-05-25 | 2002-12-05 | Schering Corporation | Use of azetidinone substituted derivatives in the treatment of alzheimer's disease |
-
2002
- 2002-01-25 RS YUP-586/03A patent/RS51449B/en unknown
- 2002-01-25 TW TW091101264A patent/TWI337083B/en not_active IP Right Cessation
- 2002-01-25 KR KR1020037009749A patent/KR100596257B1/en active IP Right Review Request
- 2002-01-25 MX MXPA03006725A patent/MXPA03006725A/en active IP Right Grant
- 2002-01-25 RS RSP-2010/0015A patent/RS20100015A/en unknown
- 2002-01-25 DK DK04000161T patent/DK1413331T3/en active
- 2002-01-25 AR ARP020100269A patent/AR033855A1/en not_active Application Discontinuation
- 2002-01-25 HU HU1500186A patent/HU230253B1/en unknown
- 2002-01-25 DE DE60222773T patent/DE60222773T2/en not_active Expired - Lifetime
- 2002-01-25 SI SI200230630T patent/SI1413331T1/en unknown
- 2002-01-25 PT PT04000161T patent/PT1413331E/en unknown
- 2002-01-25 RU RU2003126184/15A patent/RU2356550C2/en active
- 2002-01-25 SI SI200230471T patent/SI1353696T1/en unknown
- 2002-01-25 EP EP04000161A patent/EP1413331B1/en not_active Expired - Lifetime
- 2002-01-25 ES ES04000161T patent/ES2290562T3/en not_active Expired - Lifetime
- 2002-01-25 ES ES02714773T patent/ES2274013T3/en not_active Expired - Lifetime
- 2002-01-25 DK DK02714773T patent/DK1353696T3/en active
- 2002-01-25 HU HU0303915A patent/HUP0303915A3/en not_active Application Discontinuation
- 2002-01-25 IL IL15644502A patent/IL156445A0/en unknown
- 2002-01-25 US US10/057,323 patent/US20020151536A1/en not_active Abandoned
- 2002-01-25 PT PT02714773T patent/PT1353696E/en unknown
- 2002-01-25 CA CA2562982A patent/CA2562982C/en not_active Expired - Fee Related
- 2002-01-25 ME MEP-278/08A patent/MEP27808A/en unknown
- 2002-01-25 PL PL368653A patent/PL208110B1/en unknown
- 2002-01-25 AU AU2002247019A patent/AU2002247019C1/en active Active
- 2002-01-25 CZ CZ20032030A patent/CZ301871B6/en not_active IP Right Cessation
- 2002-01-25 CN CNB028072081A patent/CN100509058C/en not_active Expired - Lifetime
- 2002-01-25 WO PCT/US2002/002009 patent/WO2002058732A2/en active Application Filing
- 2002-01-25 SK SK50001-2012A patent/SK288217B6/en not_active IP Right Cessation
- 2002-01-25 EP EP02714773A patent/EP1353696B1/en not_active Expired - Lifetime
- 2002-01-25 SK SK948-2003A patent/SK287988B6/en not_active IP Right Cessation
- 2002-01-25 CA CA002563051A patent/CA2563051A1/en not_active Abandoned
- 2002-01-25 JP JP2002559066A patent/JP4777602B2/en not_active Expired - Lifetime
- 2002-01-25 DE DE60216890T patent/DE60216890T2/en not_active Expired - Lifetime
- 2002-01-25 CZ CZ2010307A patent/CZ309209B6/en not_active IP Right Cessation
- 2002-01-25 AT AT04000161T patent/ATE374641T1/en active
- 2002-01-25 NZ NZ525921A patent/NZ525921A/en not_active IP Right Cessation
- 2002-01-25 BR BR0206654-8A patent/BR0206654A/en not_active Application Discontinuation
- 2002-01-25 CA CA002434682A patent/CA2434682C/en not_active Expired - Lifetime
- 2002-01-25 AT AT02714773T patent/ATE348649T1/en active
- 2002-05-01 US US10/136,968 patent/US7030106B2/en not_active Expired - Lifetime
-
2003
- 2003-06-15 IL IL156445A patent/IL156445A/en unknown
- 2003-07-23 ZA ZA2003/05693A patent/ZA200305693B/en unknown
- 2003-07-25 NO NO20033355A patent/NO331512B1/en not_active IP Right Cessation
- 2003-12-18 HK HK04106306A patent/HK1063607A1/en not_active IP Right Cessation
- 2003-12-18 HK HK03109220A patent/HK1056696A1/en not_active IP Right Cessation
-
2004
- 2004-05-20 CL CL200401174A patent/CL2004001174A1/en unknown
- 2004-11-29 US US10/998,400 patent/US7612058B2/en active Active
-
2005
- 2005-06-22 US US11/158,429 patent/US20060199793A1/en not_active Abandoned
-
2007
- 2007-02-20 CY CY20071100238T patent/CY1108000T1/en unknown
- 2007-05-28 JP JP2007141163A patent/JP4937836B2/en not_active Expired - Lifetime
- 2007-08-29 US US11/897,227 patent/US20080058306A1/en not_active Abandoned
- 2007-11-12 JP JP2007293724A patent/JP2008088184A/en active Pending
- 2007-11-28 AR ARP070105283A patent/AR064012A2/en unknown
- 2007-12-03 CY CY20071101535T patent/CY1107045T1/en unknown
-
2008
- 2008-05-13 IL IL191417A patent/IL191417A/en active IP Right Grant
-
2011
- 2011-02-09 EC EC2011004702A patent/ECSP11004702A/en unknown
-
2012
- 2012-01-31 JP JP2012018544A patent/JP2012087149A/en not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2562982A1 (en) | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | |
JP2004521893A5 (en) | ||
WO2002058733B1 (en) | Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications | |
CA2460340A1 (en) | Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors | |
JP2004532186A5 (en) | ||
ZA200402104B (en) | Methods for treating or preventing vascular inflammation using sterol absorption inhibitors | |
JP2004521894A5 (en) | ||
JP2004532868A5 (en) | ||
RU2003126187A (en) | APPLICATION OF SUBSTITUTED AZETIDINONES FOR TREATMENT OF SYSTOSTEROLEMIA | |
JP2004517916A5 (en) | ||
JP2005504092A5 (en) | ||
CA2614885C (en) | Methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities | |
IL108112A (en) | Synergistic combination of a cholesterol biosynthesis inhibitor and a beta-lactam cholesterol absorption inhibitor | |
JP2009513713A5 (en) | ||
PT1392287E (en) | Use of azetidinone substituted derivatives in the treatment of alzheimer`s disease | |
RU2003126185A (en) | COMBINATIONS OF INHIBITOR (INHIBITORS) OF SUCTION OF STERIN WITH MODIFIER (MODIFIERS) OF BLOOD INTENDED FOR TREATMENT OF PATHOLOGICAL CONDITIONS OF VESSELS | |
CA2504878A1 (en) | Cholesterol absorption inhibitors for the treatment of demyelination | |
WO2006007312A2 (en) | Co-administration of dehydroepiandrosterone (dhea) congener with pharmaceutically active agents for treating inflammation | |
US20080227831A1 (en) | Food extracts for treatment of lipoprotein abnormalities and skin diseases and skin disorders | |
KR100792098B1 (en) | Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis | |
US20140271864A1 (en) | Therapeutic compositions for bone repair | |
JP4839309B2 (en) | Antithrombotic agent | |
JP2005529900A (en) | Catechin multimers as therapeutic drug delivery agents | |
RU2005121909A (en) | PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE | |
RU2266736C2 (en) | Method and pharmaceutical compositions usable for inhibiting arteriosclerosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20140127 |